Facing CAR T Cell Challenges on the Deadliest Paediatric Brain Tumours.

1. Introduction

Central nervous system (CNS) tumours are the most common solid cancers in childhood, as well as the leading cause of cancer-related death in children. Paediatric CNS tumours comprise 25% of the childhood cancer diagnoses [ 1 ]. Current treatments are far from optimal. Despite their great heterogeneity, affecting their location and molecular mutations, all tumours are managed the same way: surgery, chemotherapy, and/or radiotherapy.

During the last decades, significant treatment advances have extended overall survival rates (60–70%), but outcomes for children with unresectable, relapsed, or refractory tumours remain dismal. Children with disseminated disease and younger age at the time of diagnosis have a particularly poor prognosis, with a 5-year survival of 15–30% [ 2 , 3 ]. Even the cure is paid at a high price; the adverse effects of current treatments on the developing brain leave these children with long-term dramatic sequelae. Their quality of life is drastically affected by neurologic irreversible effects, endocrine disease, cognitive and developmental disorders, and the possibility of generating secondary malignancies [ 4 ].

Paediatric CNS tumours have not been as extensively studied as the adult ones. They differ in many aspects, such as clinical presentation, histological distribution, gene mutations, embryological origins, location, and the tumour microenvironment (TME), making them respond differently to the treatments [ 5 , 6 ]. Moreover, we must consider that the paediatric immune system is developing and age-dependent, leading to differences in treatment response [ 7 ].

Advances in molecular characterisation in the last years have brought the identification of new potential targeted molecular therapies that are being tested in early-phase clinical trials [ 5 , 8 ].

Despite this, the long-term survival of these young patients remains unacceptably low. Furthermore, the use of pharmacologic therapies for paediatric brain cancers can be particularly challenging due to the low permeability of the brain–blood barrier (BBB) and the lack of approved novel agents [ 9 ].

Recently, with the increased understanding of CNS immunology, along with the reported clinical success of chimeric antigen receptor T (CAR T) cells in haematological malignancies, CAR T cell immunotherapy has opened new therapeutic avenues for a targeted approach to eliminate cancer cells while sparing healthy brain tissue.

However, paediatric brain tumours represent a challenge for successful immunotherapy treatment. They possess unique characteristics, including low mutational burden, tumour heterogeneity that leads to tumour evasion, location, the barrier generated by the BBB, the immunosuppressive TME, and the treatment-related toxicities that may cause fatal consequences on the CNS [ 10 ].

In this review, we will focus mainly on the challenges of CAR T cell therapy in the more prevalent high-grade CNS paediatric brain tumours, such as medulloblastoma, ependymoma, and high-grade gliomas. Atypical teratoid/rhabdoid (AT/RT) is also one of the deadliest brain tumours but, also, it is very rare [ 11 ]. We are going to discuss the potential strategies to overcome these hurdles.

2. CAR T Cell Immunotherapy

Adoptive cell therapy (ACT) is one of the most promising strategies used in cancer immunotherapy [ 12 ]. ACT consists of the transfer of immune cells to a patient after selection, genetic manipulation, and ex vivo expansion to enhance antitumour activity. ACTs include tumour-infiltrating lymphocytes (TILs), T cell receptor (TCR) T cells, CAR T cells, and natural killer (NK) cells [ 13 ]. ACT has achieved high regression rates in several cancer types; however, lower rates have been reported in others, especially solid cancers [ 14 , 15 ]. Within ACT therapies using effector T cells, CAR T cells have emerged as a powerful strategy harnessing the power of the immune system to eradicate cancer [ 16 ].

CAR T cells involve the genetic modification of autologous or donor T cells to recognise a specific antigen. CARs incorporate an extracellular antigen-binding domain, usually derived from a single-chain variable fragment (scFv) of a monoclonal antibody, which is fused via a transmembrane linker to an intracytoplasmic signalling domain (CD3z). This basic engineered construct forms a first generation CAR. The addition of one or two costimulatory domains, which are needed to promote T cell activation and functionality, create second and third generation CARs, respectively [ 17 , 18 ]. Additionally, CAR T cells can be used as delivery vehicles of inflammatory cytokines (IL-7, IL-12, IL-15, IL-18, IL-23), antibody fragments, or other biomolecules that enhance their antitumour activity, known as fourth generation, armoured CAR T cells or TRUCKS-T cells redirected for universal cytokine-mediated killing [ 19 , 20 ]. Upon antigen recognition, the intracellular signals trigger CAR T cell activation, which, in turn, secrete perforin/granzyme and inflammatory cytokines, leading to tumour cell killing. Besides recognising tumour specific antigens, CAR T cells can also target tumour-associated antigens (TAAs) and immunosuppressive cells within the TME.

Nowadays, there are five CAR T cell therapies approved by the Food and Drug Administration for refractory large B-cell lymphoma, acute lymphoblastic leukaemia, mantle cell lymphoma, follicular lymphoma, and multiple myeloma. In this context, anti-CD19 CAR T cells have demonstrated consistent antitumour efficacy in children and adults affected by relapsed B-cell malignancies, with the percentage of complete remissions ranging from 70 to 94% in the different trials [ 21 ]. Even though there has been remarkable success in B-cell malignancies, clinical trials testing CAR T cells for solid tumours have only reported sporadic and transient objective responses [ 22 , 23 , 24 , 25 , 26 , 27 , 28 ]. CAR T cells offer some advantages over chemotherapeutic drugs, including targeting multiple tumour antigens [ 29 ]. Nevertheless, lack of specific tumour antigens, inefficient traffic of CAR T cells to the tumour site, or the hostile TME that avoids T cell activation, proliferation, and survival are some of the issues accounting for the failure of CAR T cell therapy in solid tumours. In the specific case of brain tumours, other aspects must be considered, such as the difficulty to trespass the BBB or the need to avoid inflammation or any other treatment-related toxicity. In this regard, Abramson et al. reported CD19 CAR T cells could target CNS diffuse B-cell large lymphoma cells, proving that CAR T cells can bypass the BBB and encouraging further research for using CAR T cells for brain tumours [ 30 ]. Others have also shown the efficient trafficking of CAR T cells to the paediatric CNS [ 31 , 32 , 33 ].

For paediatric patients, additional caution is required, as their brain is in development and any damage may cause life-long side effects [ 34 ].

Most of the clinical trials are generally focused on adult patients, mainly in glioblastoma (GBM), showing a modest efficacy [ 26 ]. However, these studies have served as a demonstration of the feasibility and safety of CAR T cells to treat brain tumours, paving the way to extend further the research in this field and to include more paediatric patients. As a result of this increased interest in testing CAR T cell therapies in paediatric CNS tumours, a search in clinicaltrials.gov typing “CAR” and “brain tumours” shows a total of 10 registered trials actively recruiting patients ( Table 1 ).

3. Overview of High-Grade CNS Paediatric Tumours

In this section, we will give a rough summary of the most common high-grade CNS tumours in children. There is an extensive bibliography on this topic; since that is beyond the scope of this review, see [ 35 , 36 , 37 ] for an overview.

3.1. Medulloblastoma

Medulloblastoma (MB) is a highly aggressive embryonal neuroepithelial tumour (World Health Organization (WHO) grade IV) that usually arises from the cerebellum or dorsal brainstem. MB accounts for nearly 20% of all CNS tumours in children. Current standard therapies based on surgery, chemotherapy, and radiotherapy have increased the survival rate but with devastating long-term toxicities [ 38 ]. WHO classifies MB into four histological groups: large cell and anaplastic, nodular desmoplastic, extensive nodularity, and classic. Additionally, MB is divided into four molecular subgroups: wingless/integrated (WNT), sonic hedgehog (SHH), group 3, and group 4 [ 36 , 39 ]. MB presents great heterogeneity, even within each subgroup. These subgroups differ in many features, such as cells of origin, tumour vasculature/architecture, molecular mutations, alterations in epigenetic regulators, and prognosis [ 5 , 36 , 40 ].

The WNT subgroup is characterised by the activation of the WNT pathway. It comprises 10% of all MBs and has the best clinical outcome prediction, with a 5-year overall survival (OS) >95%.

The SHH subgroup comprises very heterogeneous tumours that share the overexpression of the SHH pathway. This subgroup represents 30% of all MB, with a 5-year OS of 70%.

Group 3 represents 25% of all MB and has the worst prognosis among the subgroups, with a 5-year OS of 40–50% and half of the patients presenting metastasis at diagnosis. The underlying molecular drivers have not yet been characterised, although MYC amplification and gain or loss of chromosome function confers a poor prognosis.

Group 4 is the least understood group but the most prevalent. This group represents 35% of all MBs, with a 5-year OS of 75–90% [ 8 , 40 ]. Multiple histone mutations and epigenetic aberrations have been found in this subtype.

Some targeted therapies in early clinical trials for the SHH group and decreases in the chemo and radio doses are being implemented to achieve the same efficacy as that achieved for the WNT group, but there are no specific treatments developed for groups 3 and 4 [ 5 , 36 ].

3.2. Paediatric High-Grade Gliomas

Paediatric high-grade gliomas (pHGGs) comprises four types: diffuse midline glioma, H3 K27-altered; diffuse hemispheric glioma, H3 G34-mutant; diffuse paediatric-type high-grade glioma, H3 wildtype and IDH wildtype; and infant-type hemispheric glioma [ 41 ], as classified by the WHO [ 39 ], and represent 8–12% of all primary brain tumours in children. Of note, glioblastoma is no longer used in the setting of a paediatric-type neoplasm. pHHGs are very aggressive, with a low survival rate. Despite numerous approaches and molecular data, the 5-year survival rate is still ranging 15–35% [ 41 , 42 ]. The treatment involves a combination of surgery, radiation, and chemotherapy. Histologically, pHGG are identical to the adult HGGs, but the molecular genetics and genomic alteration patterns are unique. Epigenetic changes are common in these tumours. pHGGs carry different and mutually exclusive histone gene mutations specific to tumour location, receptor tyrosine kinase mutations, and mutations in the tumour suppressor gene TP53. pHGGs present with extensive tumour heterogeneity. Although different pHGG subgroups have been proposed in terms of anatomical location, clinical outcome, histone mutations, or pathway alterations, their great heterogeneity complicates their classification and treatment [ 8 , 43 , 44 , 45 , 46 ]. In addition, the molecular genetics of pHGGs differ between infant and older children with HGG [ 47 , 48 ]. Targeted therapies are also under investigation in early clinical trials but, to date, they have not conferred a higher survival, even in combination with standard treatments [ 35 , 49 ].

Diffuse midline gliomas (DMG) are rare tumours characterised by their aggressiveness and their infiltrative growth pattern [ 50 ]. DMGs represent 80% of all paediatric brain tumours that occur in the brainstem. DMGs have no cure and only less than 10% of patients survive beyond 2 years from the time of diagnosis [ 51 ]. Their treatment remains very challenging since their location within the brainstem makes surgical resection inappropriate. Radiotherapy is the standard of care and the combination with chemotherapy has not shown any benefit. Around 85% of DMG carry a K27M mutation in histone H3 gene or, less commonly, in the related HIST1H3B gene [ 52 ].

3.3. Ependymomas

Ependymomas account for 10% of primary intracranial tumours in children, being the third most common CNS tumour in this age group. They locate in the brain, posterior fossa, spinal cord, and supratentorial region. There are nine subgroups based on molecular analysis depending on the age, location, and biology but, even within those subgroups, there are subtypes with dismal differences in prognosis. Two-thirds of the tumours are in the posterior fossa. Posterior fossa ependymoma group A (PFEPN-A) is the most aggressive but molecular genetic studies have shown a very low mutational burden, with low somatic mutations. Posterior fossa ependymoma group B (PFEPN-B) tumours display frequent large-scale copy number gains and losses, and have better outcomes. More than 70% of supratentorial ependymomas are defined by highly recurrent gene fusions in the NF-κB subunit gene RELA (ST-EPN-RELA) [ 36 , 53 , 54 ]. The current standard of care is tumour resection and radiation, with chemotherapy giving no substantial survival advantages.

4. Challenges and Opportunities of Car T Cell Therapy in Paediatric CNS Tumours

4.1. Challenges for Paediatric Brain Tumours

The lower clinical success of CAR T cells in solid tumours is most likely multifactorial, but heterogeneous tumour antigen expression, limited infiltration of T cells into the tumour, and the immunosuppressive TME are the main hurdles. In the case of paediatric brain tumours, there are additional challenges, including the anatomical location, the BBB barrier, the specific immune function of the CNS, and the necessity to avoid toxicities. Toxicities may cause long-term sequelae, including not only morbidities and secondary neoplasia, but also social-economic implications [ 55 ]. Some of the opportunities presented by CAR T cells are summarised in Figure 1 .

4.1.1. Location

Paediatric and adult CNS tumours typically emerge from different tissues. In total, 54 to 70% of all brain tumours in children are present in the posterior fossa (including the brainstem and cerebellum), while only 15–20% of adult brain tumours are in this location [ 56 ].

MB, ependymoma, and brain stem glioma are common posterior fossa brain tumours in children. Although these are less frequent in children younger than 1 year of age, the posterior fossa is the most common site of brain tumours in the first decade of life. Tumours occurring in this area are usually of either neuronal or glial origin [ 57 ]. Neurosurgery is the mainstay of treatment in posterior fossa tumours in children, with the goal of safe, maximal resection of the tumour. Location is still a challenge for surgical treatment, with the consequent dismal prognosis for unresectable tumours [ 58 ].

4.1.2. Blood–Brain Barrier

The BBB is a highly regulated barrier between the brain and other organs to protect the brain from toxins, pathogens, and inflammation. However, simultaneously, it hinders the entry of many treatments. The BBB is composed of capillary endothelial, pericytes, astrocytes, neurons, and the extracellular matrix conforming to a neurovascular unit that protects the brain and maintain homeostasis [ 59 ]. Regarding the ability of immune cells to trespass the BBB, the CNS was traditionally considered an immunoprivileged site, but that idea is not accurate anymore [ 60 ]. The trafficking of immune cells is tightly regulated [ 61 ]. In the absence of neuroinflammation, immune surveillance occurs via draining lymphatics to deep cervical deep nodes, with rare translocation of immune cells across the BBB. These specific immune events occur under precise endothelial cell signalling and immune cell-shape fluctuation, together with an exquisite balance in the expression of adhesion molecules [ 62 , 63 , 64 ].

In contrast, in response to excessive inflammatory signals, peripheral adaptive and innate immune cells, including monocytes, neutrophils, and B and T cells can enter the CNS, where they execute distinct cell-mediated effects to maintain the homeostasis of the brain and avoid damage from inflammation [ 60 , 65 ]. The CNS-resident immune system is mainly comprised of innate immune cells called resident macrophages and microglia. These myeloid cells are highly specialised but also very plastic, and they respond immediately to any changes in CNS homeostasis, becoming reactive and promoting inflammation [ 66 ]. This way, in response to inflammation, including the one produced by tumours’ brain stromal cells, high levels of immunosuppressive cytokines, such as TGFβ or IL-10, are secreted. This secretion favours tumour growth and complicates satisfactory treatment outcomes [ 60 , 67 , 68 ].

Regarding the BBB permeability, the heterogeneity of paediatric brain tumours must be considered when applying CAR T cell treatments. Phoenix TN et al. showed that, in MB, even within the same group of tumours, the different subtypes differ in the functionality of the BBB presented. Whereas the WNT subtype presents an aberrant vasculature, making a dysfunctional BBB and leading to accumulation of antitumour treatment, the SHH subtype has an intact BBB, making it less susceptible to treatment and, therefore, less curable [ 69 ]. Knowing the state of the BBB and how it can be manipulated can enhance CAR T cell therapy treatment.

4.1.3. Tumour Microenvironment

The composition of the TME is crucial to elucidate treatment response to CAR T cell therapies. The TME is formed by a close interaction between tumour and non-tumour cells. Non-tumour cells include microglial cells, endothelial cells, pericytes, fibroblasts, and immune cells. While several of these cell types are also prevalent in brain tumours, some important features distinguish the brain tumour stroma from other tissues. The crosstalk among the different cells and the response to cytokines contribute to tumour growth and outcome to treatment [ 70 ]. Different immunosuppressive cells can also be found as regulatory T cells (Tregs), tumour-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs), which express cytokines associated with immune suppression, tolerance, and homeostasis [ 71 ]. Additionally, tumour cells can express immune inhibitory ligands that inhibit T cell activity, increase T cell exhaustion and promote the formation of a hostile TME [ 60 ]. Microglia are the resident macrophages of the CNS. Under physiological conditions, they exist in a resting state. After a stimulus, they activate, producing proinflammatory cytokines and chemokines to restore brain homeostasis [ 72 ]. In response to a microenvironmental signal, macrophages polarise to a different state. This polarisation can be summarised on M1 and M2. Both are key regulators of cancer progression. M1 have antitumor properties, whereas M2 macrophages promote tumour angiogenesis, immunosuppression, and stromal activation. The interaction between tumour cells and macrophages promotes mainly an M2 switch [ 73 ].

Comparing with myeloid cells, the presence of T cells in the TME is low, thus contributing to T cell exhaustion and lack of T cell persistence. Besides, the immunosuppressive cytokines released by TAMs lead to T cell senescence [ 74 ]

Immune checkpoint inhibitors have emerged as a promising therapy to unblock antitumour T cell responses but have led to some disappointing results in early phase clinical trials for paediatric tumours [ 4 , 43 , 53 ]. Programmed death ligand 1 (PD-L1) expression in paediatric tumours has been low in general, ranging from 0 to 36% PDL-1 positivity, depending on tumour type.

To properly induce an immune response against a tumour, we need to increase the immunogenicity of the tumour niche. Unlike adult brain tumours, in paediatric patients, the immune cell infiltration has not shown any correlation with tumour grade or mutational load, suggesting new strategies must focus on boosting the antitumour response in the tumour instead of reversing the immune escape mechanisms [ 7 ].

Paediatric CNS tumours have characteristics of “cold tumours” phenotype. They present low numbers of TILs with limited activity [ 2 ]. Several factors contribute to T cell infiltration, such as cytokines, integrins, tumour neoantigens, and tumour vasculature, having an important role in response to CAR T cell therapy [ 61 ].

Recruitment of immune cells to the tumour is also dependent on cytokines and chemokines. The scarcity of these cytokines in immunological “cold” tumours contributes to the maintenance of the immunosuppressive microenvironment and the failure of the immune system to eradicate tumour cells. Approaches that ensure the availability of these cytokines in the microenvironment of tumours without increasing their presence systemically must be developed. Besides, cold tumours lack substantial CD8 + T cell infiltration needed for antitumour immune response and surveillance.

Additionally, we need to consider that different paediatric CNS tumours have a distinctive immunophenotype. Pilocytic astrocytoma and ependymoma have higher antitumour T cell infiltration than MB, which is highly immunosuppressed. GBM, ependymoma, and MB exhibit a myeloid immunosuppressive TME, with a high proportion of M2 macrophages and poor recruitment of immune cells. Diao S et al. showed that MBs are cold tumours with a noninflammatory and immunosuppressive TME that leads to poor recruitment of immune cells [ 75 ].

TAMs tend to be pro-tumorigenic in brain tumours, producing low levels of proinflammatory cytokines and contributing to low immune T cell infiltration, although their role is still controversial and it seems tumour-context dependent [ 68 ]. While, in MB, TAMs have been reported to have an antitumoral role [ 76 ], in gliomas, inhibition of TAMs leads to a blockade in tumour progression [ 76 , 77 ]. Furthermore, TAMs contribute to the release of immunosuppressive cytokines, such as IL-10 and TGF-β, that promote tumour growth and decrease response to CAR T cell therapy [ 68 , 78 ].

By contrast, DMGs are not highly immunosuppressive tumours. They include relatively noninflammatory macrophages and low tumour immune infiltration, suggesting limited antitumour immune surveillance [ 79 ].

Thus, strategies aiming to reprogramme the tumour immunophenotype and boost immune cell recruitment and activation would increase antitumour immune responses within the TME [ 68 ]. Moreover, strategies to increase T cell persistence will enhance CAR T cell therapy.

4.1.4. Lack of Specific Tumour Antigens

The low tumour mutational load in paediatric brain tumours produces few neoantigens, making it more difficult to find targets for CAR T cell therapy, and challenging T cell activation and response to immunotherapy [ 80 ]. Accordingly, the low mutational burden will fail in promoting an existing T cell immune response, such as immune checkpoint inhibitors, making it ineffective [ 2 , 4 ]. The lack of specific tumour antigens leads to the development of CAR T cell therapy-targeting TAAs that can also be expressed at low levels on normal cells, leading to toxicities ( Table 2 ). Some clinical and preclinical studies have identified B7 homolog 3 (B7-H3), EGFRvIII, ephrin type-A receptor 2 (EphA2), HER 2, and IL13Ra2 as promising TAAs overexpressed on some paediatric CNS tumours (see Table 2 and references [ 81 , 82 , 83 , 84 , 85 , 86 , 87 ]).

CAR T cells targeting HER2, IL13Rα2, EphA2, B7-H3, and disialoganglioside GD2 (GD2) have been performed, showing efficacy [ 26 , 27 , 82 , 83 , 84 , 86 , 90 , 91 , 100 , 101 ]. Recently, Haydar D et al. established a hierarchy for the expression of the antigens B7-H3, GD2, IL13Rα2, and HER2, the most common neoantigens expressed on CNS paediatric tumours [ 102 ]. The ongoing clinical trials of CAR T cells targeting TAAs in children and young adults with recurrent or refractory CNS tumours are shown in Table 1 .

Regardless of the efforts, still antigen escape and lack of CAR T cell persistence are among the main causes of treatment failure [ 24 , 103 , 104 , 105 , 106 ]. In a GMB patient, the intracavitary and intraventricular infusion of IL13Rα2 CAR T cells showed an initial remarkable response for 7.5 months. Although the procedure showed limited adverse effects, the patient eventually relapsed due to antigen-escape phenotype [ 26 ]. Additionally, a study in GBM patients treated with EGFRvIII-CAR T cells administered intravenously showed trafficking of the CAR T cells to tumour cells, although the efficacy was inhibited by the local TME and antigen heterogeneity [ 107 ].

In the past, the infusion of HER-2 CAR T cells in GBM raised some concerns about efficacy and persistence in some clinical trials. In a phase I clinical trial, anti-HER2 CAR-T cells were administered intravenously in HER2-expressing GBM patients, including some children. CAR T cell persistence was observed for 1 year. About half of the patients showed clinical benefits, tumour heterogeneity being the main obstacle for better response rates [ 27 ]. Modifications of the CAR T design and targeting of several TAAs should be devised to maximise efficacy of this therapy [ 27 ].

Epigenetic modulators could restore immunogenicity. Paediatric brain tumours carry fewer somatic mutations and more epigenetic alterations than adult ones. The methylation profile represents a preserved molecular memory for the cell of origin and, during the disease, shows a characteristic pattern for each discrete tumour entity. Epigenetic modulators, such as histone deacetylase inhibitors (HDACis) or DNA methyltransferases (DNMTi), in combination with CAR T cell therapies, can increase effectiveness [ 108 ].

4.1.5. Toxicity

Although CAR T cell therapies have become a powerful tool in the last decades, with encouraging outcomes, especially in haematological malignancies, they also harbour toxicities that impact the morbidity and occasionally mortality of cancer patients [ 109 , 110 ].

CAR T-cell-associated toxicities are considered unique, in contrast to side effects caused by chemotherapy, which are often nonspecific and can cause permanent multiorgan damage. As a consequence of CAR T specificity, many of its associated toxicities are on-target and occur when CAR T cells are expanding, eradicated, or exhausted [ 111 ].

Cytokine release syndrome (CRS) is the most common type of toxicity caused by CAR T cells. CRS can cause headache, nausea, fever, malaise, anorexia, myalgias, hypotension, and can include multiorgan dysfunction and needs urgent intervention [ 112 , 113 ]. The severity of CRS varies among different scales. CRS or related neurotoxicity are other complications that have been observed in patients treated with CAR T CD19 for B-cell acute lymphoid leukaemia [ 84 , 114 ]. Moreover, toxicities related to the on-target off-tumour effect should be considered.

While some studies have correlated toxicity symptoms with in vivo CAR T cell expansion, in others, this correlation is not that clear [ 115 ]. The mechanism is not fully understood, but cytokine release by CAR T cells plays a significant role in this syndrome. Among them, IL-6, IFNγ, IL-15, IL-8, IL-10, and IL-2 are found to be elevated in the serum of patients experiencing CRS [ 112 , 113 , 116 ]. Several reports demonstrated that CRS usually occurs within the first week following CAR T-cell infusion [ 117 , 118 ]. Moreover, Teachey DT and collaborators showed a strong correlation between the severity of CRS and the highest levels of CAR-T cells and serum IL-6 [ 119 ]. Furthermore, in leukaemias, studies of Norelli M et al. using xenotolerant murine models and Giavridis T et al. in SCID-beige mice showed that CRS was associated with an increase in IL-1 and IL-6, a hallmark of CRS, and that the monocytes and not CAR T cells were the major source of both cytokines in CRS [ 120 , 121 ].

The second major side effect developed by patients treated with CAR T cell therapies is neurologic toxicity and, in particular, the immune effector-cell-associated neurotoxicity syndrome (ICANS) [ 110 , 122 ]. ICANS is associated with disruption of the BBB and increased cerebrospinal fluid (CSF) cytokine levels, and can present as aphasia, an altered mental state, tremor, seizures, headache, and life-threatening cerebral oedema, often occurring concurrently with or following CRS [ 123 ]. The most severe cases of ICANS have been associated mainly with patients who develop CRS and take place at the same time as CRS or some days later. The pathogenesis is even less clear than for CRS but, similarly, ICANS occurs when the peak of CAR T cells is reached [ 115 , 124 ]. Since severe ICANS has been related to increased CSF protein and cytokine levels, it has been suggested that this toxicity is triggered by both an increase in BBB permeability and local production of cytokines by cells within the CNS [ 91 , 124 ].

Other adverse effects regarding the administration of CAR T cell therapies include persistent cytopenias, infections, and tumour lysis syndrome [ 125 , 126 ]. Besides, the on-target off-tumour toxicity is an unavoidable side effect when CAR T cells target tumour-specific antigens. If the tumour-specific antigen is also expressed by tissue stem cells, this toxicity is extremely hazardous, with the risk of tissue destruction [ 127 ].

Mount CW et al. reported lethal neurotoxicity after infusion of anti-GD-2 CAR T cells in a patient-derived orthotopic xenograft model with H3K27M+ DMGs of the thalamus. This toxicity was not observed for a patient-derived orthotopic xenograft model of H3K27M+ DMGs of the pons or spinal cord. These findings highlight the importance of tumour location, monitoring, and neurointensive care management [ 91 ]. Besides, clinical trials are showing that GD2 CAR T cell therapy for DIPG and spinal cord DMG are safe and show signs of clinical benefit [ 128 ]. In some reports, the adverse events caused by the CAR T cells have been related to the tumour burden, suggesting that treatment of small brainstem tumours may reduce CRS or neurotoxicity [ 91 , 129 ]. These results could be life-changing for the outcomes of children with paediatric brain tumours.

4.2. Overcoming the Challenges by CAR T Cells

The use of CART cell therapy in paediatric brain tumours can be a useful strategy for those tumours with suboptimal outcomes and treatment possibilities. However, successful clinical outcome strategies that facilitate trespassing the BBB, increase T cell infiltration, and improve in vivo CAR T cell persistence and functionality need to be developed and tailored to the different tumours and subtypes ( Table 3 and Figure 1 ).

4.2.1. CAR T Cells Directed to the Immunosuppressive TME

The immunosuppressive TME hinders the success of CAR T cell therapy. Even in the case that CAR T cells could reach their target antigens, the TME inhibits effector T cell function, hampering their antitumour effect. The brain has immunosuppressive mechanisms to mitigate the inflammatory state [ 60 , 67 , 68 ]. Poor CAR T cell persistence can inhibit the antitumour effect. Several approaches to increase CAR T cell persistence without increasing toxicities are under investigation. CD28 and 41BB are the main CAR T co-stimulatory domains used. 41BB CAR T cells have shown higher persistence than CD28 costimulatory domain, which is associated with rapid expansion. Other costimulatory domains or the incorporation of both can increase the persistence of CAR T cells in CNS tumours [ 74 ].

Moreover, immunosuppressive molecules and cells within the TME can decrease the function and persistence of T cells. TAMs in the brain hamper the availability of cytokines, contributing to low T cell infiltration. CAR T cells targeting TAMs and, therefore, able to reprogramme the TME have been recently developed for ovarian cancer [ 181 ]. Moreover, in a recent publication, antiFOLR2 CAR T cells targeting TAM in murine models of ovarian cancer, colon cancer, and melanoma were able to reprogramme the TME and improve the efficacy of CAR T cells [ 181 ]. In a murine model of GBM, Li Y et al. designed a TGFβ-resistant EGFRvIII CAR T showing increased survival. They also found polarisation of microglia from a protumorigenic towards a proinflammatory phenotype [ 138 ]. The TME can be remodelled by the production of cytokines. Alizadeh D. et al. showed in a GBM model that the increased production of IFNγ by CAR T cells provides immune-stimulatory effects that changed the tumour immune landscape, including both myeloid and lymphoid compartments to promote a more activated and less suppressive TME [ 182 ]. Moreover, some studies have shown the role of IFNγ in inhibiting TAM-induced immunosuppression and monocyte differentiation into immunosuppressive M2 macrophage phenotype, thus preventing TAM generation and functions [ 183 ].

TRUCKS are CAR T cells engineered with the inducible release of cytokines. CAR T cells releasing IL-12, IL15, and IL-18 have been studied in preclinical models, increasing efficacy even in advanced tumours [ 130 , 131 ].

These cytokines increase IFN-γ secretion, favouring T cell infiltration and persistence, as well as decrease the level of proangiogenic molecules, reactivating the endogenous immune system [ 132 ]. For CNS tumours, the local and the controlled administration of these immunomodulatory cytokines is paramount to minimise toxicities, since high toxicity has been related to their systemic application [ 133 ].

In a syngeneic model of GBM Agliardi J et al. showed that the local administration of IL12 improved CAR T cell function, eliminating tumour growth. IL12 was also able to modulate the TME, and increase CAR T cell persistence and infiltration of T cells [ 134 ]. In a phase 1 clinical trial in patients with HGG, the controlled intracerebral expression of IL-12 was shown to be safe. The production of IL-12 was regulated by a ligand-inducible expression switch and controlled by the oral activator veledimex. The results showed tolerability and an increase in TILs [ 184 ]. IL-18 release has also been incorporated in some CAR T therapies. This therapy showed potent antitumour efficacy, both for melanoma [ 185 ] and in a pancreatic tumour [ 130 ] model of immunocompetent mice. Its functioning has been further explored in other tumour-bearing mouse models, arising as a promising therapy for solid tumours [ 186 ]. IL-15, a cytokine with a role in T cell survival and antitumour activity, is an alternative TRUCK strategy. Alizadeh D et al. showed that CAR T cells expanded in IL15 preserved a stem-like memory T cell (T SCM ) phenotype and improved their metabolic fitness, resulting in superior in vivo antitumour activity [ 187 ]. Moreover, GD2 CAR T cells expressing IL-15 were enriched in stem-cell-like cells and promoted enhanced CAR T antitumour effect and expansion in a paediatric tumour model of neuroblastoma [ 188 ]. Besides, IL-7 secretion, together with IL-15, has been used in a CAR T strategy to extend T cell persistence [ 189 ].

Although many preclinical studies have shown the feasibility of using TRUCKS, further research is warranted in paediatric CNS tumours. The selection of the appropriate interleukin(s) for each tumour type to produce a change in the immune state of the TME is essential to boost CAR T cell effector functions without increasing toxicities [ 123 , 133 ].

Despite several trials that are currently testing armoured CAR Ts, at the moment, none of them are focused on brain tumours [ 135 , 136 ].

CAR T cells designed to express proinflammatory cytokines could balance the microenvironment immune milieu from tolerant to inflammatory, improving antitumour immune response [ 22 ]. In this regard, Jin L et al. showed how CAR T cells expressing IL-8 receptors (CXCR1 or CXCR2) increased the intratumoral trafficking of CAR T cells and enhanced antitumour responses in several preclinical models of aggressive tumours, including GBM [ 137 ].

Moreover, the platelet-derived growth factor receptor α (PDGFRA) is uniquely expressed by fibroblasts in the adult heart [ 93 , 190 ], and it is dysregulated in a subset of pHGGs and DIPG tumours, driving glioma formation and associated with worse prognosis [ 46 , 94 , 95 , 96 , 97 ]. Xiao W et al. have shown that PDGFRA CAR T cells exhibited potent killing activity toward PDGFRA-positive rhabdomyosarcoma cells in vitro and in vivo; the same approach can be applied to pHGG tumours with activation of PDGFRA [ 142 , 191 ].

Radiotherapy can increase tumour immunogenicity but the neurologic effects and neurocognitive morbidity associated with radio- and chemotherapy are of major concern for the long-term survivors [ 192 ].

Gene-editing techniques, such as CRISPR-Cas9, that can disrupt a gene of interest are under investigation. The disruption of T cell inhibitory molecules, such as PD1, CTLA-4, TIM-3, or TIGIT, in CAR T cells can increase persistence and, therefore, treatment efficacy [ 74 ]. In this context, in a preclinical model of GBM, Choi BD et al. showed that the intraventricular infusion of an EGFRvIII CAR T resistant to PD1 inhibition prolonged survival and achieved complete and durable cures in some animals [ 193 ].

Therefore, CAR T cell strategies should consider these characteristics and address the recruitment, activation, and retention of tumour-specific effector immune cells [ 79 ].

Angiogenesis: Abnormal tumour blood vessel is another characteristic of solid tumours, including some paediatric CNS tumours, that hinders CAR T cell infiltration.

Some paediatric brain tumours are highly angiogenic, such as HGG, but the benefit of antiangiogenic therapy in children is not clear. Some clinical trials are studying the efficacy of antiangiogenic treatments on paediatric brain tumours. Although it is a safe procedure, the antitumour effect is poor, and one of the main problems they face is the inability to cross the BBB [ 194 ].

As for other approaches, adult GBM has been used as a model for tumour angiogenesis, making the extrapolation of the results to paediatric tumours insufficient [ 195 ].

HGGs and grade III MB express high levels of the proangiogenic factor vascular endothelial growth factor (VEGF) and PDGFR [ 194 ]. Bao et al. found that glioma cancer stem cells (CSCs) in comparison to non-CSCs, produce elevated amounts of VEGF [ 196 ].

Targeting VEGF will not only decrease or normalise the tumour vasculature, but will improve tumour immunity. VEGF functions also as an immunosuppressor molecule that blocks the maturation of dendritic cells, decreases T cell proliferation, and increases the number of Tregs, as well as MDSC activity [ 139 ]. Anti-VEGFR2 CAR T will likely improve tumour immunity while normalising tumour vasculature. This treatment seems more indicated to early stages of the disease, although it has not been tested in paediatric CNS tumours yet [ 140 ].

Placental growth factor (PlGF) is a member of the VEGF family and is involved in bone-marrow-derived cell activation, endothelial stimulation, pathologic angiogenesis, and wound healing [ 98 , 99 ]. The role of PIGF in tumour promotion is controversial, with some studies showing the involvement of PIGF in tumour growth and others showing the opposite [ 98 ]. Around 90% of primary MBs express PIGF, as well as other paediatric brain tumours, and correlate with poor survival [ 98 ]. A phase I clinical trial to study different doses of a humanised antibody against PIFG has already been completed in paediatric patients with relapsed or refractory MB ( NCT02748135 ), although no results have been reported. PIGF is also expressed in some other paediatric CNS tumours, such as gliomas, ependymomas, and AT/RT tumours, making this approach a therapeutic opportunity. Targeting the tumour vasculature will decrease hypoxia but also increase oxygen levels, immune cell infiltration, and therapeutic delivery.

This CAR T cell therapy alone or in combination with another strategy, such as immune checkpoint inhibitors, or local CAR T administration could improve survival, as has been shown for other paediatric solid tumours [ 142 ].

4.2.2. Trespassing the BBB

Several strategies have been used to facilitate the delivery of therapeutic agents, including transient BBB disruption by using hypertonic solutions or low-intensity pulsed ultrasounds, nanoparticle-based carriers, or the use of alternative routes to CNS drug delivery (intraventricular/intrathecal or olfactory routes) [ 59 , 197 , 198 ]. In a murine model of glioma, temporal disruption of the BBB by low-intensity pulsed ultrasound increased the delivery of EGFR CAR T cells and prolonged survival of the treated mice [ 199 ]. Other approaches have emerged with real possibilities in paediatric CNS tumours.

CAR T Cell Delivery

With an inefficient effector cell trafficking, only a minor fraction of CAR T cells can be found infiltrating the tumour [ 154 ]. Nanoparticles are one of the innovative approaches that can be used as carriers for drug delivery [ 154 ]. Their physical and chemical characteristics and the possibility to attach different molecules make them an interesting tool to transport the therapeutic compound across the BBB [ 155 ]. Metallic, polymeric, and lipid nanoparticles can be used to transport the therapeutic compounds, stimulate CAR T cells before infusion, or overcome TME immunosuppression. Moreover, their pharmacokinetic and pharmacodynamic properties allow the use of low doses of immune-modulating molecules, reducing their side effects [ 154 ].

Very few studies have been explored with the use of nanoparticles for enhanced CAR T cell therapy in brain tumours, most of which have been summarised by Balakrishnan PB et al. [ 155 ].

Recently, one study revealed that a nanoparticle RNA vaccine can directly enhance the cytotoxic effect of CAR T cells and overcome insufficient stimulation and low sustainability [ 156 ].

A different approach has arisen in the last years for the use of nanoparticles. Loading CAR T cells with magnetic nanoparticles (MNPs) can increase the delivery to the tumour site, therefore, overcoming the anatomical barriers. The adsorption of effector cells to MNPs to guide and retain them using an external magnetic field (EMF) at the tumour site could increase CAR T cell infiltration and decrease CRS toxicity by reducing the number of effector cells infused [ 157 ]. This fact is very important in children, since sometimes it is difficult to obtain enough material for the generation of autologous CAR T cells for brain tumours. Sanz-Ortega L et al. showed that MNPS attached to the T cell surface can be guided and retained to the target site by an EMF without affecting their biological activity and characteristics [ 157 ]. They also showed that CD8 + T cells loaded with MNPs can be directed to a tumour expressing an antigen of interest [ 200 ].

MNPs technology has already been approved for the treatment of brain tumours by inducing intratumoral thermotherapy in patients with recurrent GBM multiforme [ 201 ].

Magnetic hyperthermia takes advantage of the susceptibility of cancer cells to high temperatures. This way, intratumorally injected MNPs generate heat after exposure to an external alternating magnetic field and, consequently, induce cell death within tumours. An advantage of this technique is the application to unresectable or difficult to access brain tumours. Another important point of the use of MNPs is that they can restore cancer-specific immune responses [ 202 ].

Although this approach can solve some of the main limitations of CAR T cell therapy, much work should still be done to understand the mechanisms of interaction between T cells and MNPs, and optimise delivery.

CAR T Cell-Derived Exosomes

Exosomes are small vesicles (30–120 nm) containing nucleic acid (DNA, mRNAs, and microRNAs) and protein cargo secreted by all cell types. They are found in body fluids, including blood, saliva, urine, breast milk, and CSF. Exosomes are viewed as specifically secreted vesicles enabling intercellular communication [ 145 ].

Recent publications have shown that exosomes derived from CAR T cells (Exo-CARs) hold great potential to target cancer cells [ 146 , 147 , 148 ]. Exo-CARs maintain the same membrane topology as CAR T cells, with the extracellular domain exposed on the surface of the exosomes, and, thus, keeping the antigen recognition capacity. Additionally, upon antigen recognition on the tumour cell, Exo-CAR releases cytotoxic effector molecules, such as granzyme B and perforin, and exerts antitumour cytotoxicity. Besides having the same antigen recognition and antitumour toxicity of CAR T cells, they possess some advantages over their parental cells. Their nanoscale size would confer an improved ability to cross this barrier over the whole cell [ 149 , 203 , 204 ]. Additionally, Exo-CAR may easily penetrate the stroma-rich matrixes and may be more helpful to treat solid tumours [ 147 , 148 ]. Moreover, recent studies by Fu W et al. and Yang P et al. in murine models of solid tumours showed that animals injected with Exo-CAR exhibited no signs of toxicity, even at the highest dose tested [ 147 , 148 ]. Furthermore, one of the studies showed Exo-CARs lack expression of inhibitory molecules, such as PD1, protecting them from T cell exhaustion and providing enhanced resistance to the immunosuppressive TME [ 148 ]. Recently, Exo-CD19 CARs have been derived from CD19CAR-expressing HEK293T cells. This strategy aims to develop “off-the-shelf” targeted CAR exosomes, avoiding the limitations of manufacturing CAR T cells from autologous PBMCs [ 146 ]. It is important to note that both platforms—CAR-T-derived exosomes and CAR T cells—can be combined and/or alternated, and this combination will probably strengthen the application for CAR-based cancer therapy in paediatric CNS tumours. However, the use of exosomes equipped with CAR molecules is still at a starting point and needs further exploration.

Routes of Administration of CAR T Cell Therapy

Delivery of CAR T cells in paediatric brain tumours is also a topic of debate. Different routes have been studied: intravenous, intraventricular, and intra-tumour-cavity, with the results favouring the last two routes. In a preclinical model of AT/RT tumours, the intraventricular or intratumoral administration of B7-H3 CAR T cells had a higher antitumour effect and reduced systemic levels of inflammatory cytokines when compared to CAR T cells administered intravenously [ 150 ]. In a xenograft mouse model of MB and ependymoma, the administration of EPHA2, HER2, or ILRα13 CAR T cells in the CSF was an effective treatment, increasing the amount of CAR T cells in contact with the tumour cells and decreasing toxicities [ 85 ].

For these two types of tumours that metastasize adjacent to the CSF, this could be the preferred administration route to decrease toxicity and bypass the BBB.

Systemic delivery of CAR T cell therapy for CNS tumours could lead to inefficient crossing of the BBB. Mulazzani et al. showed that the intravenous administration of CAR T cells was less efficient in tumour killing than the intratumor administration [ 151 ]. Nellan et al., in a xenograft murine model using different MB cells lines, showed that the HER2-BBz-CAR T cells effectively eliminated tumour cells via regional and intravenous delivery, although intravenous delivery required a high concentration of effector cells [ 152 ]. Since a high concentration of effector cells could increase on-target off-tumour toxicities, locoregional delivery is the preferred route of administration in most clinical trials ( Table 1 ). Moreover, other authors, such as Priceman PJ et al., demonstrated that intraventricular regional administration of HER2-CAR T cells was more effective and with fewer side effects than local delivery, using an orthotopic human xenograft model of breast cancer metastasis to the brain [ 153 ]. Limited investigations are available for brain tumours but, reiteratively, the local intracranial CAR T administration seems to be a better option than intravenous infusion, and, also, regional delivery could be beneficial over local infusion [ 205 ].

5. Antigen Escape

Molecular and cellular heterogeneity is one characteristic of brain tumours that hampers CAR T cell therapy. Even in the case of a uniformly expressed TAA, there is the possibility of antigen loss. Antigen escape is one of the major challenges in CAR T cell therapy, with tumour cells selecting clones that downregulate antigens targeted by effector CAR T cells.

The ideal target should be expressed on most tumour cells and, specifically, in the cancer-initiating cells, which are usually resistant to conventional therapies [ 206 , 207 , 208 , 209 ].

c-Met, CD133, and CD171 are CSC markers expressed on GBM. In GBM, CAR T cells targeting CSC markers have had remarkable success in preclinical studies [ 164 ]. Although some clinical studies are ongoing, none of them are being developed in brain tumours [ 165 ].

The tumour antigens should not be expressed on cells from healthy tissue, avoiding toxicity through on-target off-tumour effect. However, even when the target has been identified and it is mostly expressed, malignant cells can outgrow at relapse, downregulating TAA expression, which, in the case of CD19 CAR T for haematological malignancies, has been associated with splicing alternatives [ 158 , 210 ].

Moreover, CAR T cells require higher antigen densities to fully activate effector functions [ 159 , 160 , 161 , 211 ]. The heterogeneous expression of target antigens in the tumour, along with the immunosuppressive TME, lead to tumour CAR T cell killing escape when using a single antigen. One strategy to overcome this limitation is the design of CAR T constructs targeting several antigens. NKG2D CAR T cells recognise up to six ligands (NKG2DL) that are usually overexpressed on tumour cells and cells from the TME but not in healthy tissue [ 88 , 162 ]. We have previously shown that these ligands are upregulated in MB [ 89 ]. Moreover, we proved the safety and effectiveness of NKG2D CAR T cells in an in vivo model of paediatric osteosarcoma [ 163 ]. Although NKG2DL shedding has been studied as an immune escape strategy in some tumours, these ligands were not detected in serum when a cohort of paediatric brain tumours was analysed [ 7 ]. Specifically, NK cells have been shown to efficiently target paediatric DIPG tumours, reinforcing the anti-tumour effectiveness of NKG2D CAR T therapy [ 79 ].

Advances in RNA sequencing, microarray analysis, and proteomics have made it possible to identify new preclinical targets. This way, strategies that combine different approaches or CAR T cells targeting multiple antigens should be considered.

Other alternatives are to study the antitumour effect of CAR T cells expressing membrane-anchored gangliosides. One of the most studied in paediatric tumours is GD-2. GD-2 is expressed at low levels on some tissues [ 92 , 101 ] ( Table 2 ). GD-2 CAR T is already in clinical trials in neuroblastoma, osteosarcoma, and H3K27M+ DMGs [ 28 , 127 , 212 ] GD-3 is another ganglioside highly expressed on malignant gliomas; thus, this could be another candidate for CAR T cell therapy in children with CNS tumours [ 166 ].

As we previously mentioned the possibility of targeting TAMs expressing folate receptor β by an anti FOLR2 CAR T, some tumours are also positive for folate receptor α (FRα). In 95 MB patients, Liu et al. observed expression of FRα, comparing with healthy brain tissue; also, in an in vivo model, tumour growth decreased upon FRα targeting [ 143 , 144 ].

6. Toxicity

For CNS tumours, CAR T cell therapy-related toxicity could lead to catastrophic outcomes and long-life side effects, so minimisation of adverse events is critical. Preclinical research is providing novel alternatives to reduce CAR-T-associated toxicities that have to be cleared in clinical trials. The intensity of conditioning therapy, high CAR T cell dose, and CAR T cell construct design are among the main factors that lead to increased CAR T cell expansion in vivo and boost toxicity.

As an example, some groups are focusing their research on modifying the CAR structure to ameliorate toxicity by decreasing CAR-antigen binding domain affinity to micromolar affinity or altering CAR transmembrane regions to modulate cytokine secretion [ 213 ]. Other methods involve the modification of CAR T cells expressing suicide switch molecules, CAR T cells directed against tumour antigens, or pharmacological immunosuppression by using immunomodulatory pharmacologic drugs [ 172 , 173 , 174 , 175 , 176 ]. Several different approaches are already under investigation, with some of the systems being in early phase clinical trials. For paediatric CNS tumour patients, several considerations must be considered when choosing the approach. In case of life-threatening toxicity, iCasp9 irreversibly eliminate CAR T cells. Endogenous switches, such as synNotch and iCAR, regulate CAR T cells, but the time and intensity of CAR T cell activity cannot be controlled [ 177 ]. Some strategies have already been tested in clinical trials in CNS tumours, such as the CAR T expressing the gene coding for inducible caspase-9 (iCasp9). Phase I efficacy and safety trials of the CD2 CAR T iCasp9 technology have been initiated in several indications, including DIPG and spinal DMG [ 172 ] ( Table 1 ).

New methods to keep a balance between cytokine secretions and CAR T cell activation without reaching a toxicity level are needed.

Preclinical models have their limitations. Patient-derived xenografts (PDXs) have been increasingly used in translational research, but immunocompromised models create a host environment that does not recapitulate the one from the patients. The lack of an immune system hampers the potential development of some of the most common negative effects of CAR T cell therapy, on-target off-tumour effect, CRS, and neurotoxicity [ 214 ]. Adequate preclinical models should be chosen to better study brain malignancies [ 215 , 216 , 217 , 218 ]. Humanised mouse models are probably a better model to recapitulate T-cell-based therapy, but they also present some limitations, such as lack of recapitulation of CAR T cell toxicities; also, these models are expensive and difficult to obtain for routine use [ 219 ]. Syngeneic models are more economic and have a functional immune system. They also can unveil on-target off-tumour toxicities. These models present some disadvantages due to the differences in mouse and human biology, including the absence of human antigen targets and different inflammatory environment [ 220 , 221 ]. Moreover, chemokines involved in infiltration can be species-specific, limiting efficient trafficking, i.e., human IFNγ secreted for T cells, a cytokine important for tumour elimination, does not act on murine tumour stromal cells [ 222 ]. All these issues do not support the results for clinical translation.

Mathematical modelling has emerged as a tool to predict treatment response and CAR T cell dynamics. This tool can give answers about CAR T cell dosing to avoid relapse and toxicities, studying CAR T cell expansion and exhaustion and the interaction between CAR T cells and immune cells. These aspects are patient-dependent and an important feature of the success of this therapy [ 178 ]. In some studies, developed in paediatric leukaemia, the authors underlined the importance of the characteristics of the infused CAR T cells. Leon-Triana O et al., in a pilot mathematical model, used a dual target for tumour cells and the antigen present in normal cells, such as CD19 + . They showed poor CAR T cell persistence due to the immunosuppression and low levels of tumour target [ 179 ]. In brain tumours, mathematical modelling has also been applied in a model of GBM. Sahoo P et al. showed, in a CAR T cell treatment response in glioma (CARRGO) model, that the rate of cancer cell killing by CAR T cells is inversely related to the CAR T cell dose, but CAR T cell dose correlates with the proliferation and exhaustion of CAR T cells [ 180 ]. Although with some limitations, such as tumour heterogeneity and immunosuppressive TME, these in silico models are useful for predicting the behaviour of CAR T cell therapy and tumour growth.

7. Other Considerations

Optimisation of the CAR T cell manufacturing process to enrich for the population, which can contribute to sustaining an effective antitumour response, is crucial, especially when they encounter hostile conditions of solid tumours [ 167 , 182 ]. To improve the protocols for culturing time, cell density, choice of IL, including concentration and timing of supplementation, for ex vivo culture are important variables to produce an optimal clinical product [ 103 ]. Moreover, the selection of a T cell subtype with a non-alloreactive phenotype, such as memory T cells, will contribute to decreasing toxicities. Most clinical trials have been performed with CAR T cells with an effector memory phenotype, which translates to poor persistence in vivo. This lack of persistence has encouraged finding a subset of T cells that are less differentiated or with a memory phenotype [ 168 ]. T SCM are under investigation given their self-renewal capacity, engraftment potential, and ability to generate other T cell subsets. Because the frequency of these T cell subpopulations in peripheral blood is very low (2–3%), specific manufacturing processes that can enrich and expand CAR T SCM cells are already in preclinical studies [ 167 , 169 , 170 ]. Another important question is the therapeutic window of CAR T cell therapy. The density and expression on healthy tissues of TAA for CAR T cells have to be considered. The level of TAA expression on healthy tissues narrows the therapeutic window of this therapy. Moreover, the TAA density threshold for CAR T cell recognition and activation are important issues to be considered. These and other modifications that can broaden this window would be necessary to enhance efficacy [ 171 ].

8. Conclusions

Little improvement has been made in the last decades for recurrent or relapsed paediatric brain tumours. Children with CNS tumours present unique challenges due to their brain development and immature immune system. The research field in CAR T cell therapy has advanced extraordinarily, but mainly for adult patients and haematological malignancies. Given the differences in paediatric and adult CNS tumours, the results obtained from adults cannot be applied to children. Therefore, new strategies must be tailored to the unique characteristics of paediatric CNS tumours.

Future strategies with CAR T cells need to consider the hurdles of these tumours, lack of specific TAA, tumour heterogeneity, diffusion through the BBB, the TME, and the small number of patients that limit data generation. Innovative therapies, such as Exo-CAR T and nanotechnology, are promising fields due to their characteristics and advantages.

The integration of multidisciplinary data and preclinical research with the combination of different strategies will be required to maximize positive results. All these efforts will translate into breakthroughs in CAR T cell therapy for these patients with generally suboptimal clinical outcomes. Safety should always be the main consideration when assessing new treatment for these children.

Acknowledgments

We would like to acknowledge the CRIS Cancer Foundation for their continuous support to our work.

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author Contributions

Conceptualization, C.F., and A.P.-M.; methodology, C.F., L.F., L.C.-V., M.I.-N., C.M.-C. and A.P.-M.; software, C.F., L.F., M.I.-N.; investigation, C.F., L.F., L.C.-V., M.I.-N., C.M.-C.; resources, A.P.-M.; writing—original draft preparation, C.F., L.F., L.C.-V., M.I.-N., C.M.-C.; writing—review and editing, C.F., L.F., L.C.-V., M.I.-N., C.M.-C., I.E.-R., J.S. and A.P.-M.; visualization, C.F.; supervision, A.P.-M.; project administration, C.F.; funding acquisition, A.P.-M. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported in part by the National Health Service of Spain, Instituto de Salud Carlos III (ISCIII) Fondos FEDER Grant (FIS) ICI19/00052 (to A.P.-M).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Johnson K.J. Cullen J. Barnholtz-Sloan J.S. Ostrom Q.T. Langer C.E. Turner M.C. Mckean-Cowdin R. Fisher J.L. Lupo P.J. Partap S. Childhood Brain Tumor Epidemiology: A Brain Tumor Epidemiology Consortium Review Cancer Epidemiol. Biomark. Prev. 2014 23 2716 2736 10.1158/1055-9965.EPI-14-0207 PMC4257885 25192704

2. Wang S.S. Bandopadhayay P. Jenkins M.R. Towards Immunotherapy for Pediatric Brain Tumors Trends Immunol. 2019 40 748 761 10.1016/j.it.2019.05.009 31229353

3. Pérez-Martínez A. Lassaletta A. Gonzaíez-Vicent M. Sevilla J.J. Dıáz M.A. Madero L. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors J. Neurooncol. 2005 71 33 38 10.1007/s11060-004-4527-4 15719272

4. Pearson A.D.J. Rossig C. Lesa G. Diede S.J. Weiner S. Anderson J. Gray J. Geoerger B. Minard-Colin V. Marshall L.V. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients Eur. J. Cancer 2020 127 52 66 10.1016/j.ejca.2019.12.029 31986450

5. Abedalthagafi M. Mobark N. Al-Rashed M. AlHarbi M. Epigenomics and immunotherapeutic advances in pediatric brain tumors NPJ Precis. Oncol. 2021 5 34 10.1038/s41698-021-00173-4 33931704 PMC8087701

6. Hong C.S. Ho W. Piazza M.G. Ray-Chaudhury A. Zhuang Z. Heiss J.D. Characterization of the blood brain barrier in pe-diatric central nervous system neoplasms J. Interdiscip. Histopathol. 2016 4 29 33 10.5455/jihp.20160623053540 27917302 PMC5132180

7. Plant A.S. Koyama S. Sinai C. Solomon I.H. Griffin G.K. Ligon K.L. Bandopadhayay P. Betensky R. Emerson R. Dranoff G. Immunophenotyping of pediatric brain tumors: Correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response J. Neurooncol. 2018 137 269 278 10.1007/s11060-017-2737-9 29322427

8. Mueller T. Stucklin A.S.G. Postlmayr A. Metzger S. Gerber N. Kline C. Grotzer M. Nazarian J. Mueller S. Advances in Targeted Therapies for Pediatric Brain Tumors Curr. Treat. Options Neurol. 2020 22 43 10.1007/s11940-020-00651-3

9. Ransohoff R.M. Kivisäkk P. Kidd G. Three or more routes for leukocyte migration into the central nervous system Nat. Rev. Immunol. 2003 3 569 581 10.1038/nri1130 12876559

10. Foster J.B. Madsen P.J. Hegde M. Ahmed N. Cole K.A. Maris J.M. Resnick A.C. Storm P.B. Waanders A.J. Immunotherapy for pediatric brain tumors: Past and present Neuro-Oncol. 2019 21 1226 1238 10.1093/neuonc/noz077 31504801 PMC6784275

11. Biswas A. Kashyap L. Kakkar A. Sarkar C. Kumar Julka P. Cancer Management and Research Dovepress Atypical teratoid/rhabdoid tumors: Challenges and search for solutions Cancer Manag. Res. 2016 8 115 125 10.2147/CMAR.S83472 27695363 PMC5033212

12. Munhoz R.R. Postow M.A. Recent advances in understanding antitumor immunity F1000Research 2016 5 2545 10.12688/f1000research.9356.1 27803807 PMC5074378

13. Choi B.D. Maus M.V. June C.H. Sampson J.H. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies Clin. Cancer Res. 2019 25 2042 2048 10.1158/1078-0432.CCR-18-1625 30446589 PMC6445734

14. Verdegaal E.M.E. Adoptive cell therapy: A highly successful individualized therapy for melanoma with great potential for other malignancies Curr. Opin. Immunol. 2016 39 90 95 10.1016/j.coi.2016.01.004 26829458

15. Rosenberg S.A. Yang J.C. Sherry R.M. Kammula U.S. Marybeth S. Phan G.Q. Citrin D.E. Restifo N.P. Robbins P.F. John R. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunothera-py Clin. Cancer Res. 2012 17 4550 4557 10.1158/1078-0432.CCR-11-0116 PMC3131487 21498393

16. Larson R.C. Maus M.V. Recent advances and discoveries in the mechanisms and functions of CAR T cells Nat. Rev. Cancer 2021 21 145 161 10.1038/s41568-020-00323-z 33483715 PMC8353572

17. Sadelain M. Brentjens R. Rivière I. The basic principles of chimeric antigen receptor (CAR) design Cancer Discov. 2008 141 520 529 10.1158/2159-8290.CD-12-0548 PMC3667586 23550147

18. Shirasu N. Kuroki M. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: Architecture and outcomes Anticancer Res. 2012 32 2377 2383 22641678

19. Shum T. Kruse R.L. Rooney C.M. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities Expert Opin. Biol. Ther. 2018 18 653 664 10.1080/14712598.2018.1473368 29727246 PMC6084433

20. Yeku O.O. Brentjens R.J. Soc B. Author T. Armored CAR T-cells: Utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy HHS Public Access Author manuscript Biochem. Soc. Trans. 2016 44 412 418 10.1042/BST20150291 27068948 PMC5529098

21. Wang Z. Wu Z. Liu Y. Han W. New development in CAR-T cell therapy J. Hematol. Oncol. 2017 10 53 10.1186/s13045-017-0423-1 28222796 PMC5320663

22. Akhavan D. Alizadeh D. Wang D. Weist M.R. Shepphird J.K. Brown C.E. CAR T cells for brain tumors: Lessons learned and road ahead Immunol. Rev. 2019 290 60 84 10.1111/imr.12773 31355493 PMC6771592

23. Marofi F. Motavalli R. Safonov V.A. Thangavelu L. Yumashev A.V. Alexander M. Shomali N. Chartrand M.S. Pathak Y. Jarahian M. CAR T cells in solid tumors: Challenges and opportunities Stem Cell Res. Ther. 2021 12 81 10.1186/s13287-020-02128-1 33494834 PMC7831265

24. Sterner R.C. Sterner R.M. CAR-T cell therapy: Current limitations and potential strategies Blood Cancer J. 2021 11 69 10.1038/s41408-021-00459-7 33824268 PMC8024391

25. Yong C.S.M. Dardalhon V. Devaud C. Taylor N. Darcy P.K. Kershaw M.H. CAR T-cell therapy of solid tumors Immunol. Cell Biol. 2017 95 356 363 10.1038/icb.2016.128 28003642

26. Brown C.E. Alizadeh D. Starr R. Weng L. Wagner J.R. Naranjo A. Ostberg J.R. Blanchard M.S. Kilpatrick J. Simpson J. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy N. Engl. J. Med. 2016 375 2561 2569 10.1056/NEJMoa1610497 28029927 PMC5390684

27. Ahmed N. Brawley V. Hegde M. Bielamowicz K. Kalra M. Landi D. Robertson C. Gray T.L. Diouf O. Wakefield A. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial JAMA Oncol. 2017 3 1094 1101 10.1001/jamaoncol.2017.0184 28426845 PMC5747970

28. Louis C.U. Savoldo B. Dotti G. Pule M. Yvon E. Myers G.D. Rossig C. Russell H.V. Diouf O. Liu E. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma Blood 2011 118 6050 6056 10.1182/blood-2011-05-354449 21984804 PMC3234664

29. Choe J.H. Watchmaker P.B. Simic M.S. Gilbert R.D. Li A.W. Krasnow N.A. Downey K.M. Yu W. Carrera D.A. Celli A. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma Sci. Transl. Med. 2021 13 eabe7378 10.1126/scitranslmed.abe7378 33910979 PMC8362330

30. Abramson J.S. McGree B. Noyes S. Plummer S. Wong C. Chen Y.B. Palmer E. Albertson T. Ferry J.A. Arrillaga-Romany I.C. Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lym-phoma N. Engl. J. Med. 2017 377 783 784 10.1056/NEJMc1704610 28834486

31. Engelhardt B. Vajkoczy P. Weller R.O. The movers and shapers in immune privilege of the CNS Nat. Immunol. 2017 18 123 131 10.1038/ni.3666 28092374

32. Slaney C.Y. Kershaw M.H. Darcy P.K. Trafficking of T cells into tumors Cancer Res. 2014 74 7168 7174 10.1158/0008-5472.CAN-14-2458 25477332

33. Tan Y. Pan J. Deng B. Ling Z. Song W. Xu J. Duan J. Wang Z. Yu X. Chang A.H. Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL Cancer Immunol. Immunother. 2021 70 1979 1993 10.1007/s00262-020-02829-9 33416942 PMC10992445

34. Byer L. Kline C. Mueller S. Clinical trials in pediatric neuro-oncology: What is missing and how we can improve CNS Oncol. 2016 5 5 10.2217/cns-2016-0016 PMC5619017 27616346

35. Cacciotti C. Fleming A. Ramaswamy V. Advances in the molecular classification of pediatric brain tumors: A guide to the galaxy J. Pathol. 2020 251 249 261 10.1002/path.5457 32391583

36. Liu K.W. Pajtler K.W. Worst B.C. Pfister S.M. Wechsler-Reya R.J. Molecular mechanisms and therapeutic targets in pediatric brain tumors Sci. Signal. 2017 10 eaaf759 10.1126/scisignal.aaf7593 28292958

37. Pollack I.F. Agnihotri S. Broniscer A. Childhood brain tumors: Current management, biological insights, and future directions J. Neurosurg. Pediatr. 2019 23 261 273 10.3171/2018.10.PEDS18377 30835699 PMC6823600

38. Martin A.M. Raabe E. Eberhart C. Cohen K.J. Management of Pediatric and Adult Patients with Medulloblastoma Curr. Treat. Options Oncol. 2014 15 581 594 10.1007/s11864-014-0306-4 25194927 PMC4216607

39. Louis D.N. Perry A. Wesseling P. Brat D.J. Cree I.A. Figarella-Branger D. Hawkins C. Ng H.K. Pfister S.M. Reifenberger G. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary Neuro-Oncol. 2021 23 1231 1251 10.1093/neuonc/noab106 34185076 PMC8328013

40. Thomas A. Noël G. Medulloblastoma: Optimizing care with a multidisciplinary approach J. Multidiscip. Healthc. 2019 12 335 347 10.2147/JMDH.S167808 31118657 PMC6498429

41. Braunstein S. Raleigh D. Bindra R. Mueller S. Haas-Kogan D. Pediatric high-grade glioma: Current molecular landscape and therapeutic approaches J. Neurooncol. 2017 134 541 549 10.1007/s11060-017-2393-0 28357536

42. Fangusaro J. Warren K. Hipp S.J. Jallo G. Gururangan S. Pediatric high grade glioma: A review and update on tumor clinical characteristics and biology Front. Oncol. 2012 2 105 10.3389/fonc.2012.00105 22937526 PMC3426754

43. Wang Z. Guo X. Gao L. Wang Y. Guo Y. Xing B. Ma W. Classification of pediatric gliomas based on immunological profiling: Implications for immunotherapy strategies Mol. Ther.-Oncol. 2021 20 34 47 10.1016/j.omto.2020.12.012 PMC7851498 33575469

44. McCrea H.J. Bander E.D. Venn R.A. Reiner A.S. Iorgulescu J.B. Puchi L.A. Schaefer P.M. Cederquist G. Greenfield J.P. Sex, age, anatomic location, and extent of resection influence outcomes in children with high-grade glioma Neurosurgery 2015 77 443 452 10.1227/NEU.0000000000000845 26083157

45. Jones C. Karajannis M.A. Jones D.T.W. Kieran M.W. Monje M. Baker S.J. Becher O.J. Cho Y.J. Gupta N. Hawkins C. Pediatric high-grade glioma: Biologically and clinically in need of new thinking Neuro-Oncol. 2017 19 153 161 10.1093/neuonc/now101 27282398 PMC5464243

46. Mackay A. Burford A. Carvalho D. Izquierdo E. Fazal-Salom J. Taylor K.R. Bjerke L. Clarke M. Vinci M. Nandhabalan M. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma Cancer Cell 2017 32 520 537.e5 10.1016/j.ccell.2017.08.017 28966033 PMC5637314

47. Clarke M. Mackay A. Ismer B. Pickles J.C. Tatevossian R.G. Newman S. Bale T.A. Stoler I. Izquierdo E. Temelso S. Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes Cancer Discov. 2020 10 942 963 10.1158/2159-8290.CD-19-1030 32238360 PMC8313225

48. Varlet P. Le Teuff G. Le Deley M.C. Giangaspero F. Haberler C. Jacques T.S. Figarella-Branger D. Pietsch T. Andreiuolo F. Deroulers C. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial Neuro-Oncol. 2020 22 116 127 10.1093/neuonc/noz142 31419298 PMC6954414

49. Rizzo D. Ruggiero A. Martini M. Rizzo V. Maurizi P. Riccardi R. Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment Biomed Res. Int. 2015 2015 215135 10.1155/2015/215135 26448930 PMC4584033

50. Louis D.N. Perry A. Reifenberger G. von Deimling A. Figarella-Branger D. Cavenee W.K. Ohgaki H. Wiestler O.D. Kleihues P. Ellison D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary Acta Neuropathol. 2016 131 803 820 10.1007/s00401-016-1545-1 27157931

51. Srikanthan D. Taccone M.S. Van Ommeren R. Ishida J. Krumholtz S.L. Rutka J.T. Diffuse intrinsic pontine glioma: Current insights and future directions Chin. Neurosurg. J. 2021 7 6 10.1186/s41016-020-00218-w 33423692 PMC7798267

52. Himes B.T. Zhang L. Daniels D.J. Treatment strategies in diffuse midline gliomas with the H3K27M mutation: The role of convection-enhanced delivery in overcoming anatomic challenges Front. Oncol. 2019 9 31 10.3389/fonc.2019.00031 30800634 PMC6375835

53. Mack S.C. Pajtler K.W. Chavez L. Okonechnikov K. Bertrand K.C. Wang X. Erkek S. Federation A. Song A. Lee C. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling Nature 2018 553 101 105 10.1038/nature25169 29258295 PMC5993422

54. Wang G. Jia Y. Ye Y. Kang E. Chen H. Wang J. He X. Identification of key methylation differentially expressed genes in posterior fossa ependymoma based on epigenomic and transcriptome analysis J. Transl. Med. 2021 19 174 10.1186/s12967-021-02834-1 33902636 PMC8077736

55. Plant-Fox A.S. O’Halloran K. Goldman S. Pediatric brain tumors: The era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae Curr. Probl. Cancer 2021 45 100777 10.1016/j.currproblcancer.2021.100777 34303558

56. Klonou A. Piperi C. Gargalionis A.N. Papavassiliou A.G. Molecular Basis of Pediatric Brain Tumors NeuroMol. Med. 2017 19 256 270 10.1007/s12017-017-8455-9 28748347

57. Muzumdar D. Ventureyra E.C.G. Treatment of posterior fossa tumors in children Expert Rev. Neurother. 2010 10 525 546 10.1586/ern.10.28 20367206

58. Moussalem C. Ftouni L. Mrad Z.A. Amine A. Hamideh D. Baassiri W. Bali B. Najjar M. Pediatric posterior fossa tumors outcomes: Experience in a tertiary care center in the Middle East Clin. Neurol. Neurosurg. 2020 197 106170 10.1016/j.clineuro.2020.106170 32861036

59. Lawther B.K. Kumar S. Krovvidi H. Blood-brain barrier Contin. Educ. Anaesth. Crit. Care Pain 2011 11 128 132 10.1093/bjaceaccp/mkr018

60. Sampson J.H. Gunn M.D. Fecci P.E. Ashley D.M. Brain immunology and immunotherapy in brain tumours Nat. Rev. Cancer 2020 20 12 25 10.1038/s41568-019-0224-7 31806885 PMC7327710

61. Grabovska Y. Mackay A. O’Hare P. Crosier S. Finetti M. Schwalbe E.C. Pickles J.C. Fairchild A.R. Avery A. Cockle J. Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity Nat. Commun. 2020 11 4324 10.1038/s41467-020-18070-y 32859926 PMC7455736

62. Kipnis J. Multifaceted interactions between adaptive immunity and the central nervous system Science 2016 353 766 771 10.1126/science.aag2638 27540163 PMC5590839

63. Carrithers M.D. Visintin I. Kang S.J. Janeway C.A. Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment Brain 2000 123 1092 1101 10.1093/brain/123.6.1092 10825349

64. Greenwood J. Heasman S.J. Alvarez J.I. Prat A. Lyck R. Engelhardt B. Review: Leucocyte-endothelial cell crosstalk at the blood-brain barrier: A prerequisite for successful immune cell entry to the brain Neuropathol. Appl. Neurobiol. 2011 37 24 39 10.1111/j.1365-2990.2010.01140.x 20946472

65. Negi N. Das B.K. CNS: Not an immunoprivilaged site anymore but a virtual secondary lymphoid organ Int. Rev. Immunol. 2018 37 57 68 10.1080/08830185.2017.1357719 28961037

66. Prinz M. Priller J. The role of peripheral immune cells in the CNS in steady state and disease Nat. Neurosci. 2017 20 136 144 10.1038/nn.4475 28092660

67. Roesch S. Rapp C. Dettling S. Herold-Mende C. Molecular Sciences When Immune Cells Turn Bad-Tumor-Associated Microglia/Macrophages in Glioma Int. J. Mol. Sci. 2018 19 436 10.3390/ijms19020436 29389898 PMC5855658

68. Quail D.F. Joyce J.A. The Microenvironmental Landscape of Brain Tumors Cancer Cell 2017 31 326 341 10.1016/j.ccell.2017.02.009 28292436 PMC5424263

69. Phoenix T.N. Patmore D.M. Boop S. Boulos N. Jacus M.O. Patel Y.T. Roussel M.F. Finkelstein D. Goumnerova L. Perreault S. Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype Cancer Cell 2016 29 508 522 10.1016/j.ccell.2016.03.002 27050100 PMC4829447

70. Batista A. Riedemann L. Vardam T. Jain R.K. Targeting the Tumor Microenvironment to Enhance Pediatric Brain Cancer Treatment Cancer J. (USA) 2015 21 307 313 10.1097/PPO.0000000000000125 26222083

71. Terry R.L. Meyran D. Ziegler D.S. Haber M. Ekert P.G. Trapani J.A. Neeson P.J. Immune profiling of pediatric solid tumors J. Clin. Investig. 2020 130 3391 3402 10.1172/JCI137181 32538896 PMC7324195

72. Wu S.Y. Watabe K. The roles of microglia/macrophages in tumor progression of brain cancer and metastatic disease Front. Biosci.-Landmark 2017 22 1805 1829 10.2741/4573 PMC5658785 28410147

73. Liu J. Geng X. Hou J. Wu G. New insights into M1/M2 macrophages: Key modulators in cancer progression Cancer Cell Int. 2021 21 389 10.1186/s12935-021-02089-2 34289846 PMC8296555

74. Upreti D. Bakhshinyan D. Bloemberg D. Vora P. Venugopal C. Singh S.K. Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors Front. Immunol. 2020 11 599253 10.3389/fimmu.2020.599253 33281826 PMC7689359

75. Diao S. Gu C. Zhang H. Yu C. Immune cell infiltration and cytokine secretion analysis reveal a non-inflammatory microenvironment of medulloblastoma Oncol. Lett. 2020 20 397 10.3892/ol.2020.12260 33193857 PMC7656115

76. Maximov V. Chen Z. Wei Y. Robinson M.H. Herting C.J. Shanmugam N.S. Rudneva V.A. Goldsmith K.C. MacDonald T.J. Northcott P.A. Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma Nat. Commun. 2019 10 2410 10.1038/s41467-019-10458-9 31160587 PMC6546707

77. Pyonteck S.M. Akkari L. Schuhmacher A.J. Bowman R.L. Sevenich L. Quail D.F. Olson O.C. Quick M.L. Huse J.T. Teijeiro V. CSF-1R inhibition alters macrophage polarization and blocks glioma progression Nat. Med. 2013 19 1264 1272 24056773 10.1038/nm.3337 PMC3840724

78. Lampson L.A. Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? Front. Oncol. 2016 8 10.3389/fonc.2018.00128 PMC5141244 28003994

79. Lieberman N.A.P. Degolier K. Kovar H.M. Davis A. Hoglund V. Stevens J. Winter C. Deutsch G. Furlan S.N. Vitanza N.A. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: Implications for development of immunotherapy Neuro-Oncol. 2019 21 83 94 10.1093/neuonc/noy145 30169876 PMC6303470

80. Chalmers Z.R. Connelly C.F. Fabrizio D. Gay L. Ali S.M. Ennis R. Schrock A. Campbell B. Shlien A. Chmielecki J. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden Genome Med. 2017 9 34 10.1186/s13073-017-0424-2 28420421 PMC5395719

81. Zhou W.T. Jin W.L. B7-H3/CD276: An Emerging Cancer Immunotherapy Front. Immunol. 2021 12 701006 10.3389/fimmu.2021.701006 34349762 PMC8326801

82. Majzner R.G. Theruvath J.L. Nellan A. Heitzeneder S. Cui Y. Mount C.W. Rietberg S.P. Linde M.H. Xu P. Rota C. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors Clin. Cancer Res. 2019 25 2560 2574 10.1158/1078-0432.CCR-18-0432 30655315 PMC8456711

83. Maachani U.B. Tosi U. Pisapia D.J. Mukherjee S. Marnell C.S. Voronina J. Martinez D. Santi M. Dahmane N. Zhou Z. B7-H3 as a Prognostic Biomarker and Therapeutic Target in Pediatric central nervous system Tumors Transl. Oncol. 2020 13 365 371 10.1016/j.tranon.2019.11.006 31887631 PMC6938869

84. Patterson J.D. Henson J.C. Breese R.O. Bielamowicz K.J. Rodriguez A. CAR T Cell Therapy for Pediatric Brain Tumors Front. Oncol. 2020 10 1582 10.3389/fonc.2020.01582 32903405 PMC7435009

85. Donovan L.K. Delaidelli A. Joseph S.K. Bielamowicz K. Fousek K. Holgado B.L. Manno A. Srikanthan D. Gad A.Z. Van Ommeren R. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma Nat. Med. 2020 26 720 731 10.1038/s41591-020-0827-2 32341580 PMC8815773

86. Okada H. Low K.L. Kohanbash G. McDonald H.A. Hamilton R.L. Pollack I.F. Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas J. Neurooncol. 2008 88 245 250 10.1007/s11060-008-9566-9 18324354 PMC2561297

87. Kawakami M. Kawakami K. Takahashi S. Abe M. Puri R.K. Analysis of interleukin-13 receptor α2 expression in human pediatric brain tumors Cancer 2004 101 1036 1042 10.1002/cncr.20470 15329913

88. Nausch N. Cerwenka A. NKG2D ligands in tumor immunity Oncogene 2008 27 5944 5958 10.1038/onc.2008.272 18836475

89. Fernández L. Portugal R. Valentín J. Martín R. Maxwell H. González-Vicent M. Díaz M.Á. de Prada I. Pérez-Martínez A. In vitro natural killer cell immunotherapy for medulloblastoma Front. Oncol. 2013 3 94 10.3389/fonc.2013.00094 23626949 PMC3630393

90. O’Rourke D.M. Nasrallah M.P. Desai A. Melenhorst J.J. Mansfield K. Morrissette J.J.D. Martinez-Lage M. Brem S. Maloney E. Shen A. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma Sci. Transl. Med. 2017 9 57 68 10.1126/scitranslmed.aaa0984 28724573 PMC5762203

91. Mount C.W. Majzner R.G. Sundaresh S. Arnold E.P. Kadapakkam M. Haile S. Labanieh L. Hulleman E. Woo P.J. Rietberg S.P. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas letter Nat. Med. 2018 24 572 579 10.1038/s41591-018-0006-x 29662203 PMC6214371

92. Nazha B. Inal C. Owonikoko T.K. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy Front. Oncol. 2020 10 1000 10.3389/fonc.2020.01000 32733795 PMC7358363

93. Basciani S. Mariani S. Arizzi M. Ulisse S. Rucci N. Jannini E.A. Della Rocca C. Manicone A. Carani C. Spera G. Expression of Platelet-Derived Growth Factor-A (PDGF-A), PDGF-B, and PDGF Receptor-and-during Human Testicular Development and Disease J. Clin. Endocrinol. Metab. 2002 87 2310 2319 11994382 10.1210/jcem.87.5.8476

94. Paugh B.S. Qu C. Jones C. Liu Z. Adamowicz-Brice M. Zhang J. Bax D.A. Coyle B. Barrow J. Hargrave D. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease J. Clin. Oncol. 2010 28 3061 3068 10.1200/JCO.2009.26.7252 20479398 PMC2903336

95. Koschmann C. Zamler D. Mackay A. Robinson D. Wu Y.-M. Doherty R. Marini B. Tran D. Garton H. Muraszko K. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma Oncotarget 2016 7 65696 65706 10.18632/oncotarget.11602 27582545 PMC5323185

96. Paugh B.S. Zhu X. Qu C. Endersby R. Diaz A.K. Zhang J. Bax D.A. Carvalho D. Reis R.M. Onar-Thomas A. Molecular and Cellular Pathobiology Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas Cancer Res. 2013 73 6219 6229 10.1158/0008-5472.CAN-13-1491 23970477 PMC3800209

97. Puget S. Philippe C. Bax D.A. Varlet J.B. Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas PLoS ONE 2012 7 30313 10.1371/journal.pone.0030313 PMC3289615 22389665

98. Snuderl M. Batista A. Kirkpatrick N.D. De Almodovar C.R. Riedemann L. Walsh E.C. Anolik R. Huang Y. Martin J.D. Kamoun W. Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma Cell 2013 152 1065 1076 10.1016/j.cell.2013.01.036 23452854 PMC3587980

99. De Falco S. The discovery of placenta growth factor and its biological activity Exp. Mol. Med. 2012 44 1 9 10.3858/emm.2012.44.1.025 22228176 PMC3277892

100. Krenciute G. Krebs S. Torres D. Wu M.F. Liu H. Dotti G. Li X.N. Lesniak M.S. Balyasnikova I.V. Gottschalk S. Characterization and functional analysis of scFv-based chimeric antigen receptors to redirect T Cells to IL13Rα2-positive glioma Mol. Ther. 2016 24 354 363 10.1038/mt.2015.199 26514825 PMC4817815

101. Chow K.K. Naik S. Kakarla S. Brawley V.S. Shaffer D.R. Yi Z. Rainusso N. Wu M.F. Liu H. Kew Y. T cells redirected to EphA2 for the immunotherapy of glioblastoma Mol. Ther. 2013 21 629 637 10.1038/mt.2012.210 23070117 PMC3589173

102. Haydar D. Houke H. Chiang J. Yi Z. Odé Z. Caldwell K. Zhu X. Mercer K.S. Stripay J.L. Shaw T.I. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery Neuro-Oncology 2021 23 999 1011 10.1093/neuonc/noaa278 33320196 PMC8168826

103. Jafarzadeh L. Masoumi E. Fallah-Mehrjardi K. Mirzaei H.R. Hadjati J. Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward Front. Immunol. 2020 11 10.3389/fimmu.2020.00702 PMC7188834 32391013

104. Li X. Chen W. Mechanisms of failure of chimeric antigen receptor T-cell therapy Curr. Opin. Hematol. 2019 26 427 433 10.1097/MOH.0000000000000548 31577606 PMC6791516

105. Hsieh E.M. Scherer L.D. Rouce R.H. Replacing CAR-T cell resistance with persistence by changing a single residue J. Clin. Investig. 2020 130 2806 2808 10.1172/JCI136872 32364534 PMC7260020

106. Cheng J. Zhao L. Zhang Y. Qin Y. Guan Y. Zhang T. Liu C. Zhou J. Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies Front. Oncol. 2019 9 1237 10.3389/fonc.2019.01237 31824840 PMC6882288

107. Goff S.L. Morgan R.A. Yang J.C. Sherry R.M. Robbins P.F. Restifo N.P. Feldman S.A. Lu Y.-C. Lu L. Zheng Z. Pilot trial of adoptive transfer of chimeric antigen receptor transduced T cells targeting EGFRvIII in patients with glioblastoma HHS Public Access J. Immunother. 2019 42 126 135 10.1097/CJI.0000000000000260 30882547 PMC6691897

108. Suter R.K. Rodriguez-Blanco J. Ayad N.G. Epigenetic pathways and plasticity in brain tumors Neurobiol. Dis. 2020 145 105060 10.1016/j.nbd.2020.105060 32877743

109. Morris E.C. Neelapu S.S. Giavridis T. Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy Nat. Rev. Immunol. 2021 0123456789 10.1038/s41577-021-00547-6 PMC8127450 34002066

110. Neelapu S.S. Tummala S. Kebriaei P. Wierda W. Gutierrez C. Locke F.L. Komanduri K.V. Lin Y. Jain N. Daver N. Chimeric antigen receptor T-cell therapy—Assessment and management of toxicities Nat. Rev. Clin. Oncol. 2018 15 47 62 10.1038/nrclinonc.2017.148 28925994 PMC6733403

111. June C.H. Sadelain M. Chimeric Antigen Receptor Therapy | Enhanced Reader N. Engl. J. Med. Rev. 2018 379 64 73 10.1056/NEJMra1706169 29972754 PMC7433347

112. Siegler E.L. Kenderian S.S. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights into Mechanisms and Novel Therapies Front. Immunol. 2020 11 1973 10.3389/fimmu.2020.01973 32983132 PMC7485001

113. Sharma A. De Leon G. Porter A. Grill M.F. Rosenthal A. Brown C.E. Swanson K. Mrugala M.M. CAR-T cell therapy in neuro-oncology: Applications and toxicity Neuroimmunol. Neuroinflamm. 2018 5 43 10.20517/2347-8659.2018.51

114. Wu C.Y. Roybal K.T. Puchner E.M. Onuffer J. Lim W.A. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor Science 2015 350 aab4077 10.1126/science.aab4077 26405231 PMC4721629

115. Santomasso B.D. Park J.H. Salloum D. Riviere I. Mead E. Halton E. Wang X. Senechal B. Cross J.R. Liu H. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia Cancer Discov. 2019 8 958 971 10.1158/2159-8290.CD-17-1319 PMC6385599 29880584

116. Gust J. Ponce R. Liles W.C. Garden G.A. Turtle C.J. Cytokines in CAR T Cell–Associated Neurotoxicity Front. Immunol. 2020 11 577027 10.3389/fimmu.2020.577027 33391257 PMC7772425

117. Neelapu S.S. Locke F.L. Bartlett N.L. Lekakis L.J. Miklos D.B. Jacobson C.A. Braunschweig I. Oluwole O.O. Siddiqi T. Lin Y. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma N. Engl. J. Med. 2017 377 2531 2544 10.1056/NEJMoa1707447 29226797 PMC5882485

118. Schuster S.J. Bishop M.R. Tam C.S. Waller E.K. Borchmann P. McGuirk J.P. Jäger U. Jaglowski S. Andreadis C. Westin J.R. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma N. Engl. J. Med. 2019 380 45 56 10.1056/NEJMoa1804980 30501490

119. Teachey D.T. Lacey S.F. Shaw P.A. Melenhorst J.J. Maude S.L. Frey N. Pequignot E. Gonzalez V.E. Chen F. Finklestein J. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia Cancer Discov. 2016 6 664 679 10.1158/2159-8290.CD-16-0040 27076371 PMC5448406

120. Norelli M. Camisa B. Barbiera G. Falcone L. Purevdorj A. Genua M. Sanvito F. Ponzoni M. Doglioni C. Cristofori P. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells Nat. Med. 2018 24 739 748 10.1038/s41591-018-0036-4 29808007

121. Giavridis T. van der Stegen S.J. Eyquem J. Hamieh M. Piersigilli A. Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages Physiol. Behav. 2019 176 139 148 10.1038/s41591-018-0041-7 PMC6410714 29808005

122. Lee D.W. Santomasso B.D. Locke F.L. Ghobadi A. Turtle C.J. Brudno J.N. Maus M.V. Park J.H. Mead E. Pavletic S. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells Biol. Blood Marrow Transplant. 2019 25 625 638 10.1016/j.bbmt.2018.12.758 30592986 PMC12180426

123. Rafiq S. Hackett C.S. Brentjens R.J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy Nat. Rev. Clin. Oncol. 2020 17 147 167 10.1038/s41571-019-0297-y 31848460 PMC7223338

124. Gust J. Hay K.A. Hanafi L.-A. Li D. Myerson D. Gonzalez-Cuyar L.F. Yeung C. Liles W.C. Wurfel M. Lopez J.A. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells Cancer Discov. 2021 7 1404 1419 10.1158/2159-8290.CD-17-0698 PMC5718945 29025771

125. Lee D.W. Kochenderfer J.N. Stetler-Stevenson M. Cui Y.K. Delbrook C. Feldman S.A. Fry T.J. Orentas R. Sabatino M. Shah N.N. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial Lancet 2015 385 517 528 10.1016/S0140-6736(14)61403-3 25319501 PMC7065359

126. Maude S.L. Laetsch T.W. Buechner J. Rives S. Boyer M. Bittencourt H. Bader P. Verneris M.R. Stefanski H.E. Myers G.D. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia N. Engl. J. Med. 2018 378 439 448 10.1056/NEJMoa1709866 29385370 PMC5996391

127. Hombach A.A. Abken H. Shared target antigens on cancer cells and tissue stem cells: Go or no-go for CAR T cells? Expert Rev. Clin. Immunol. 2017 13 151 155 10.1080/1744666X.2016.1221763 27546707

128. Majzner R.G. Ramakrishna S. Mochizuki A. Patel S. Chinnasamy H. Yeom K. Schultz L. Richards R. Campen C. Reschke A. Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas Clin. Trials 2021 81 CT031

129. Schuelke M.R. Wongthida P. Thompson J. Kottke T. Driscoll C.B. Huff A.L. Shim K.G. Coffey M. Pulido J. Evgin L. Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity J. Immunother. Cancer 2019 7 188 10.1186/s40425-019-0673-2 31315671 PMC6637625

130. Chmielewski M. Abken H. CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors Cell Rep. 2017 21 3205 3219 10.1016/j.celrep.2017.11.063 29241547

131. Zimmermann K. Kuehle J. Dragon A.C. Galla M. Kloth C. Rudek L.S. Sandalcioglu I.E. Neyazi B. Moritz T. Meyer J. Design and characterization of an “all-in-one” lentiviral vector system combining constitutive anti-gd2 car expression and inducible cytokines Cancers 2020 12 375 10.3390/cancers12020375 32041222 PMC7072617

132. Chmielewski M. Abken H. TRUCKS, the fourth-generation CAR T cells: Current developments and clinical translation Adv. Cell Gene Ther. 2020 3 e84 10.1002/acg2.84

133. Hawkins E.R. D’souza R.R. Klampatsa A. Armored CAR T-cells: The next chapter in T-cell cancer immunotherapy Biol. Targets Ther. 2021 15 95 105 10.2147/BTT.S291768 PMC8053711 33883875

134. Agliardi G. Liuzzi A.R. Hotblack A. De Feo D. Núñez N. Stowe C.L. Friebel E. Nannini F. Rindlisbacher L. Roberts T.A. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma Nat. Commun. 2021 12 444 10.1038/s41467-020-20599-x 33469002 PMC7815781

135. Koneru M. O’Cearbhaill R. Pendharkar S. Spriggs D.R. Brentjens R.J. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer J. Transl. Med. 2015 13 102 10.1186/s12967-015-0460-x 25890361 PMC4438636

136. Nair S. Wang J.-B. Tsao S.-T. Liu Y. Zhu W. Slayton W.B. Moreb J.S. Dong L. Chang L.-J. Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Rα Signaling Curr. Gene Ther. 2018 19 40 53 10.2174/1566523218666181116093857 30444200

137. Jin L. Tao H. Karachi A. Long Y. Hou A.Y. Na M. Dyson K.A. Grippin A.J. Deleyrolle L.P. Zhang W. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors Nat. Commun. 2019 10 4016 10.1038/s41467-019-11869-4 31488817 PMC6728370

138. Li Y. Wu H. Chen G. Wei X. Wang C. Zhou S. Huang A. Zhang Z. Zhan C. Wu Y. Arming Anti-EGFRvIII CAR-T with TGFβ Trap Improves Antitumor Efficacy in Glioma Mouse Models Front. Oncol. 2020 10 1117 10.3389/fonc.2020.01117 32974124 PMC7461942

139. Yang J. Yan J. Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity Front. Immunol. 2018 9 978 10.3389/fimmu.2018.00978 29774034 PMC5943566

140. Gururangan S. Chi S.N. Poussaint T.Y. Onar-Thomas A. Gilbertson R.J. Vajapeyam S. Friedman H.S. Packer R.J. Rood B.N. Boyett J.M. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A pediatric brain tumor consortium study J. Clin. Oncol. 2010 28 3069 3075 10.1200/JCO.2009.26.8789 20479404 PMC2903337

141. Englisch A. Altvater B. Kailayangiri S. Hartmann W. Rossig C. VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma Pediatr. Blood Cancer 2020 67 e28313 10.1002/pbc.28313 32729251

142. Han X. Wang Y. Han W.-D. Chimeric antigen receptor modified T-cells for cancer treatment Chronic Dis. Transl. Med. 2018 4 225 243 10.1016/j.cdtm.2018.08.002 30603741 PMC6309024

143. Liu H. Sun Q. Zhang M. Zhang Z. Fan X. Yuan H. Li C. Guo Y. Ning W. Sun Y. Differential expression of folate receptor 1 in medulloblastoma and the correlation with clinicopathological characters and target therapeutic potential Oncotarget 2017 8 23048 23060 10.18632/oncotarget.15480 28416738 PMC5410284

144. Lu Y.J. Chu H. Wheeler L.W. Nelson M. Westrick E. Matthaei J.F. Cardle I.I. Johnson A. Gustafson J. Parker N. Preclinical evaluation of bispecific adaptor molecule controlled folate receptor CAR-T cell therapy with special focus on pediatric malignancies Front. Oncol. 2019 9 151 10.3389/fonc.2019.00151 30941303 PMC6433934

145. Xue D. Han J. Liu Y. Tuo H. Peng Y. Current perspectives on exosomes in the diagnosis and treatment of hepatocellular carcinoma (review) Cancer Biol. Ther. 2021 22 279 290 10.1080/15384047.2021.1898728 33847207 PMC8183537

146. Tang X.J. Sun X.Y. Huang K.M. Zhang L. Yang Z.S. Zou D.D. Wang B. Warnock G.L. Dai L.J. Luo J. Therapeutic potential of CAR-T cell-derived exosomes: A cell-free modality for targeted cancer therapy Oncotarget 2015 6 44179 44190 10.18632/oncotarget.6175 26496034 PMC4792550

147. Yang P. Cao X. Cai H. Feng P. Chen X. Zhu Y. Yang Y. An W. Yang Y. Jie J. The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth Cell. Immunol. 2021 360 104262 10.1016/j.cellimm.2020.104262 33373818

148. Fu W. Lei C. Liu S. Cui Y. Wang C. Qian K. Li T. Shen Y. Fan X. Lin F. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity Nat. Commun. 2019 10 4355 10.1038/s41467-019-12321-3 31554797 PMC6761190

149. Alvarez-Erviti L. Seow Y. Yin H. Betts C. Lakhal S. Wood M.J.A. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat. Biotechnol. 2011 29 341 345 10.1038/nbt.1807 21423189

150. Theruvath J. Sotillo E. Mount C.W. Graef C.M. Delaidelli A. Heitzeneder S. Labanieh L. Dhingra S. Leruste A. Majzner R.G. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors Nat. Med. 2020 26 712 719 10.1038/s41591-020-0821-8 32341579 PMC7992505

151. Mulazzani M. Fräßle S.P. Von Mücke-Heim I. Langer S. Zhou X. Ishikawa-Ankerhold H. Leube J. Zhang W. Dötsch S. Svec M. Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice Proc. Natl. Acad. Sci. USA 2019 116 24275 24284 10.1073/pnas.1903854116 31712432 PMC6883823

152. Nellan A. Rota C. Majzner R. Lester-McCully C.M. Griesinger A.M. Mulcahy Levy J.M. Foreman N.K. Warren K.E. Lee D.W. Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells J. Immunother. Cancer 2018 6 30 10.1186/s40425-018-0340-z 29712574 PMC5925833

153. Priceman S.J. Tilakawardane D. Jeang B. Aguilar B. Murad J.P. Park A.K. Chang W.-C. Ostberg J.R. Neman J. Jandial R. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 + Breast Cancer Metastasis to the Brain Clin. Cancer Res. 2018 24 95 105 10.1158/1078-0432.CCR-17-2041 29061641 PMC7685198

154. Zottel A. Videtic Paska A. Jovčevska I. Nanotechnology Meets Oncology: Nanomaterials in brain cancer research, diagnosis and therapy Materials 2019 12 1588 10.3390/ma12101588 31096609 PMC6567262

155. Balakrishnan P.B. Sweeney E.E. Nanoparticles for Enhanced Adoptive T Cell Therapies and Future Perspectives for CNS Tumors Front. Immunol. 2021 12 600659 10.3389/fimmu.2021.600659 33833751 PMC8021848

156. Reinhard K. Rengstl B. Oehm P. Türeci Ö. Sahin U. Abstract LB-383: An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors Science 2020 367 446 453 10.1126/science.aay5967 31896660

157. Sanz-Ortega L. Rojas J.M. Barber D.F. Improving tumor retention of effector cells in adoptive cell transfer therapies by magnetic targeting Pharmaceutics 2020 12 812 10.3390/pharmaceutics12090812 PMC7557387 32867162

158. Majzner R.G. Mackall C.L. Tumor antigen escape from car t-cell therapy Cancer Discov. 2018 8 1219 1226 10.1158/2159-8290.CD-18-0442 30135176

159. Drent E. Themeli M. Poels R. de Jong-Korlaar R. Yuan H. de Bruijn J. Martens A.C.M. Zweegman S. van de Donk N.W.C.J. Groen R.W.J. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization Mol. Ther. 2017 25 1946 1958 10.1016/j.ymthe.2017.04.024 28506593 PMC5542711

160. Turatti F. Figini M. Balladore E. Alberti P. Casalini P. Marks J.D. Canevari S. Mezzanzanica D. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction J. Immunother. 2007 30 684 693 10.1097/CJI.0b013e3180de5d90 17893561

161. Walker A.J. Majzner R.G. Zhang L. Wanhainen K. Long A.H. Nguyen S.M. Lopomo P. Vigny M. Fry T.J. Orentas R.J. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase Mol. Ther. 2017 25 2189 2201 10.1016/j.ymthe.2017.06.008 28676342 PMC5589087

162. Barber A. Rynda A. Sentman C.L. Chimeric NKG2D Expressing T Cells Eliminate Immunosuppression and Activate Immunity within the Ovarian Tumor Microenvironment J. Immunol. 2009 183 6939 6947 10.4049/jimmunol.0902000 19915047 PMC2825039

163. Fernández L. Metais J.Y. Escudero A. Vela M. Valentín J. Vallcorba I. Leivas A. Torres J. Valeri A. Patiño-García A. Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells Clin. Cancer Res. 2017 23 5824 5835 10.1158/1078-0432.CCR-17-0075 28659311

164. Zhu X. Prasad S. Gaedicke S. Hettich M. Firat E. Niedermann G. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57 Oncotarget 2015 6 171 184 10.18632/oncotarget.2767 25426558 PMC4381586

165. Masoumi J. Jafarzadeh A. Abdolalizadeh J. Khan H. Philippe J. Mirzaei H. Mirzaei H.R. Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects Acta Pharm. Sin. B 2021 11 1721 1739 10.1016/j.apsb.2020.12.015 34386318 PMC8343118

166. Rossig C. Kailayangiri S. Jamitzky S. Altvater B. Carbohydrate targets for CAR T cells in solid childhood cancers Front. Oncol. 2018 8 513 10.3389/fonc.2018.00513 30483473 PMC6240699

167. Arcangeli S. Falcone L. Camisa B. De Girardi F. Biondi M. Giglio F. Ciceri F. Bonini C. Bondanza A. Casucci M. Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients Front. Immunol. 2020 11 1217 10.3389/fimmu.2020.01217 32636841 PMC7317024

168. Fernández L. Fernández A. Mirones I. Escudero A. Cardoso L. Vela M. Lanzarot D. de Paz R. Leivas A. Gallardo M. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy Front. Immunol. 2019 10 2361 10.3389/fimmu.2019.02361 31649672 PMC6795760

169. Tantalo D.G.M. Oliver A.J. Von Scheidt B. Harrison A.J. Mueller S.N. Kershaw M.H. Slaney C.Y. Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies J. Immunother. Cancer 2021 9 e002555 10.1136/jitc-2021-002555 34035114 PMC8154965

170. Alvarez-Fernández C. Escribà-Garcia L. Caballero A.C. Escudero-López E. Ujaldón-Miró C. Montserrat-Torres R. Pujol-Fernández P. Sierra J. Briones J. Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma Clin. Transl. Immunol. 2021 10 e1268 10.1002/cti2.1268 PMC8082716 33968404

171. Watanabe K. Kuramitsu S. Posey A.D. June C.H. Expanding the therapeutic window for CAR T cell therapy in solid tumors: The knowns and unknowns of CAR T cell biology Front. Immunol. 2018 9 2486 10.3389/fimmu.2018.02486 30416506 PMC6212550

172. Andrea A.E. Chiron A. Bessoles S. Hacein-Bey-Abina S. Molecular Sciences Engineering Next-Generation CAR-T Cells for Better Toxicity Management J. Mol. Sci. 2020 21 8620 10.3390/ijms21228620 PMC7696189 33207607

173. Brandt L.J.B. Barnkob M.B. Michaels Y.S. Heiselberg J. Barington T. Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review Front. Immunol. 2020 11 326 10.3389/fimmu.2020.00326 32194561 PMC7062233

174. Jones B.S. Lamb L.S. Goldman F. Di Stasi A. Improving the safety of cell therapy products by suicide gene transfer Front. Pharmacol. 2014 5 1 8 10.3389/fphar.2014.00254 25505885 PMC4245885

175. Marin V. Cribioli E. Philip B. Tettamanti S. Pizzitola I. Biondi A. Biagi E. Pule M. Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells Hum. Gene Ther. Methods 2012 23 376 386 10.1089/hgtb.2012.050 23186165 PMC4015080

176. Fedorov V.D. Themeli M. Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses Sci. Transl. Med. 2014 11 215ra172 10.1126/scitranslmed.3006597 PMC4238416 24337479

177. Moghanloo E. Mollanoori H. Talebi M. Pashangzadeh S. Faraji F. Hadjilooei F. Mahmoodzadeh H. Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs Transl. Oncol. 2021 14 101070 10.1016/j.tranon.2021.101070 33789222 PMC8027274

178. Locke F.L. Altrock P.M. Kimmel G.J. The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy Proc. Biol. Sci. 2021 288 20210229 33757357 10.1098/rspb.2021.0229 PMC8059581

179. León-Triana O. Pérez-Martínez A. Ramírez-Orellana M. Pérez-García V.M. Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept Cancers (Basel) 2021 13 703 10.3390/cancers13040703 33572301 PMC7916125

180. Sahoo P. Yang X. Abler D. Maestrini D. Adhikarla V. Frankhouser D. Cho H. Machuca V. Wang D. Barish M. Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data J. R. Soc. Interface 2020 17 20190734 10.1098/rsif.2019.0734 31937234 PMC7014796

181. Rodriguez-Garcia A. Lynn R.C. Poussin M. Eiva M.A. Shaw L.C. O’Connor R.S. Minutolo N.G. Casado-Medrano V. Lopez G. Matsuyama T. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy Nat. Commun. 2021 12 877 10.1038/s41467-021-20893-2 33563975 PMC7873057

182. Alizadeh D. Wong R.A. Gholamin S. Maker M. Aftabizadeh M. Yang X. Pecoraro J.R. Jeppson J.D. Wang D. Aguilar B. IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity Cancer Discov. 2021 11 2248 2265 10.1158/2159-8290.CD-20-1661 33837065 PMC8561746

183. Duluc D. Corvaisier M. Blanchard S. Catala L. Descamps P. Gamelin E. Ponsoda S. Delneste Y. Hebbar M. Jeannin P. Interferon-γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages Int. J. Cancer 2009 125 367 373 10.1002/ijc.24401 19378341

184. Chiocca E.A. Yu J.S. Lukas R.V. Solomon I.H. Ligon K.L. Nakashima H. Triggs D.A. Reardon D.A. Wen P. Stopa B.M. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial Sci. Transl. Med. 2019 11 eaaw5680 10.1126/scitranslmed.aaw5680 31413142 PMC7286430

185. Hu B. Ren J. Luo Y. Keith B. Young R.M. Scholler J. Zhao Y. June C.H. Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18 Cell Rep. 2017 20 3025 3033 10.1016/j.celrep.2017.09.002 28954221 PMC6002762

186. Avanzi M.P. Yeku O. Li X. Wijewarnasuriya D.P. van Leeuwen D.G. Cheung K. Park H. Purdon T.J. Daniyan A.F. Spitzer M.H. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System Cell Rep. 2018 23 2130 2141 10.1016/j.celrep.2018.04.051 29768210 PMC5986286

187. Alizadeh D. Wong R.A. Yang X. Wang D. Pecoraro J.R. Kuo C.F. Aguilar B. Qi Y. Ann D.K. Starr R. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype Cancer Immunol. Res. 2019 7 759 772 10.1158/2326-6066.CIR-18-0466 30890531 PMC6687561

188. Chen Y. Sun C. Landoni E. Metelitsa L. Dotti G. Savoldo B. Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15 Clin. Cancer Res. 2019 25 2915 2924 10.1158/1078-0432.CCR-18-1811 30617136

189. Golumba-Nagy V. Kuehle J. Hombach A.A. Abken H. CD28-ζ CAR T Cells Resist TGF-β Repression through IL-2 Signaling, Which Can Be Mimicked by an Engineered IL-7 Autocrine Loop Mol. Ther. 2018 26 2218 2230 10.1016/j.ymthe.2018.07.005 30055872 PMC6127517

190. Ivey M.J. Kuwabara J.T. Riggsbee K.L. Tallquist M.D. Platelet-derived growth factor receptor-is essential for cardiac fibroblast survival Am. J. Physiol.-Heart Circ. Physiol. 2019 317 330 344 10.1152/ajpheart.00054.2019 PMC6732481 31125253

191. Xiao W. Wang J. Wen X. Xu B. Que Y. Yu K. Xu L. Zhao J. Pan Q. Zhou P. Chimeric antigen receptor-modified T-cell therapy for platelet-derived growth factor receptor α-positive rhabdomyosarcoma Cancer 2020 126 2093 2100 10.1002/cncr.32764 32293729

192. Akkari L. Decker W.K. Torrado E. Sevenich L. Schulz M. Salamero-Boix A. Niesel K. Alekseeva T. Microenvironmental Regulation of Tumor Progression and Therapeutic Response in Brain Metastasis Front. Immunol. 2019 1 1713 10.3389/fimmu.2019.01713 PMC6667643 31396225

193. Choi B.D. Yu X. Castano A.P. Darr H. Henderson D.B. Bouffard A.A. Larson R.C. Scarfò I. Bailey S.R. Gerhard G.M. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma J. Immunother. Cancer 2019 7 304 10.1186/s40425-019-0806-7 31727131 PMC6857271

194. Ollauri-Ibáñez C. Astigarraga I. Use of antiangiogenic therapies in pediatric solid tumors Cancers 2021 13 253 10.3390/cancers13020253 PMC7827326 33445470

195. Sie M. den Dunnen W.F.A. Hoving E.W. de Bont E.S.J.M. Anti-angiogenic therapy in pediatric brain tumors: An effective strategy? Crit. Rev. Oncol. Hematol. 2014 89 418 432 10.1016/j.critrevonc.2013.09.005 24169416

196. Bao S. Wu Q. Sathornsumetee S. Hao Y. Li Z. Hjelmeland A.B. Shi Q. McLendon R.E. Bigner D.D. Rich J.N. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor Cancer Res. 2006 66 7843 7848 10.1158/0008-5472.CAN-06-1010 16912155

197. Beccaria K. Canney M. Bouchoux G. Puget S. Grill J. Carpentier A. Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: A review and perspectives Neurosurg. Focus 2020 48 E10 10.3171/2019.10.FOCUS19726 31896084

198. Hersh D.S. Wadajkar A.S. Roberts N. Perez J.G. Connolly N.P. Frenkel V. Winkles J.A. Woodworth G.F. Kim A.J. Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier Curr. Pharm. Des. 2016 22 1177 1193 10.2174/1381612822666151221150733 26685681 PMC4900538

199. Sabbagh A. Beccaria K. Ling X. Marisetty A. Ott M. Caruso H. Barton E. Kong L.-Y. Fang D. Latha K. Opening of the Blood–Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models Clin. Cancer Res. 2021 27 4325 4337 10.1158/1078-0432.CCR-20-3760 34031054 PMC9012394

200. Sanz-Ortega L. Portilla Y. Pérez-Yagüe S. Barber D.F. Magnetic targeting of adoptively transferred tumour-specific nanoparticle-loaded CD8+ T cells does not improve their tumour infiltration in a mouse model of cancer but promotes the retention of these cells in tumour-draining lymph nodes J. Nanobiotechnol. 2019 17 87 10.1186/s12951-019-0520-0 31387604 PMC6683429

201. Maier-Hauff K. Ulrich F. Nestler D. Niehoff H. Wust P. Thiesen B. Orawa H. Budach V. Jordan A. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme J. Neurooncol. 2011 103 317 324 10.1007/s11060-010-0389-0 20845061 PMC3097345

202. Kolosnjaj-Tabi J. Wilhelm C. Magnetic nanoparticles in cancer therapy: How can thermal approaches help? Nanomedicine 2017 12 573 575 10.2217/nnm-2017-0014 28244818

203. Tran T.H. Mattheolabakis G. Aldawsari H. Amiji M. Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases Clin. Immunol. 2015 160 46 58 10.1016/j.clim.2015.03.021 25842185

204. Yang T. Martin P. Fogarty B. Brown A. Schurman K. Phipps R. Yin V.P. Lockman P. Bai S. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio Pharm Res. 2015 32 2003 2014 10.1007/s11095-014-1593-y 25609010 PMC4520542

205. Brown C.E. Aguilar B. Starr R. Yang X. Chang W.C. Weng L. Chang B. Sarkissian A. Brito A. Sanchez J.F. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma Mol. Ther. 2018 26 31 44 10.1016/j.ymthe.2017.10.002 29103912 PMC5763077

206. Kaur G. Sharma P. Dogra N. Singh S. Eradicating Cancer Stem Cells: Concepts, Issues, and Challenges Options Oncol. 2018 19 20 10.1007/s11864-018-0533-1 29556842

207. Colak S. Medema J.P. Cancer stem cells—Important players in tumor therapy resistance FEBS J. 2014 281 4779 4791 10.1111/febs.13023 25158828

208. Ma S. Lee T.K. Zheng B.-J. Chan K.W. Guan X.-Y. CD133 þ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway Oncogene 2008 27 1749 1758 10.1038/sj.onc.1210811 17891174

209. Batlle E. Clevers H. Cancer stem cells revisited Nat. Med. 2017 23 1124 1134 10.1038/nm.4409 28985214

210. Davila M.L. Riviere I. Wang X. Bartido S. Park J. Chung S.S. Stefanski J. Borquez-ojeda O. Qu J. Wasielewska T. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy Sci. Transl. Med. 2014 6 224 225 10.1126/scitranslmed.3008226 24553386 PMC4684949

211. Weijtens M.E.M. Hart E.H. Bolhuis R.L.H. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production Gene Ther. 2000 7 35 42 10.1038/sj.gt.3301051 10680014

212. Straathof K. Flutter B. Wallace R. Jain N. Loka T. Depani S. Wright G. Thomas S. Cheung G.W.K. Gileadi T. Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma Sci. Transl. Med. 2020 12 eabd6169 10.1126/scitranslmed.abd6169 33239386

213. Ying Z. Huang X.F. Xiang X. Liu Y. Kang X. Song Y. Guo X. Liu H. Ding N. Zhang T. A safe and potent anti-CD19 CAR T cell therapy Nat. Med. 2019 25 947 953 10.1038/s41591-019-0421-7 31011207 PMC7518381

214. Barros L.R.C. Paixão E.A. Valli A.M.P. Naozuka G.T. Fassoni A.C. Almeida R.C. Cartmath—A mathematical model of car-t immunotherapy in preclinical studies of hematological cancers Cancers 2021 13 2914 10.3390/cancers13122941 34208323 PMC8231202

215. Hoffmann N. Fernández V. Pereira R.C. Rancati S. Pelizzoli R. De Pietri Tonelli D. A Xenotransplant Model of Human Brain Tumors in Wild-Type Mice iScience 2020 23 100831 10.1016/j.isci.2019.100813 31931429 PMC6957874

216. Jacob F. Salinas R.D. Zhang D.Y. Nguyen P.T.T. Schnoll J.G. Wong S.Z.H. Thokala R. Sheikh S. Saxena D. Prokop S. A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity Cell 2020 180 188 204.e22 10.1016/j.cell.2019.11.036 31883794 PMC7556703

217. Mariappan A. Goranci-Buzhala G. Ricci-Vitiani L. Pallini R. Gopalakrishnan J. Trends and challenges in modeling glioma using 3D human brain organoids Cell Death Differ. 2021 28 15 23 10.1038/s41418-020-00679-7 33262470 PMC7707134

218. Ballabio C. Anderle M. Gianesello M. Lago C. Miele E. Cardano M. Aiello G. Piazza S. Caron D. Gianno F. Modeling medulloblastoma in vivo and with human cerebellar organoids Nat. Commun. 2020 11 583 10.1038/s41467-019-13989-3 31996670 PMC6989674

219. Wu Y. Yu X.Z. Modelling CAR-T therapy in humanized mice EBioMedicine 2019 40 25 26 10.1016/j.ebiom.2019.01.029 30665855 PMC6413350

220. Siegler E.L. Wang P. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy Hum. Gene Ther. 2018 29 534 546 10.1089/hum.2017.243 29390873

221. Sanmamed M.F. Chester C. Melero I. Kohrt H. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies Ann. Oncol. 2016 27 1190 1198 10.1093/annonc/mdw041 26912558

222. Textor A. Listopad J.J. Le Wührmann L. Perez C. Kruschinski A. Chmielewski M. Abken H. Blankenstein T. Charo J. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ Cancer Res. 2014 74 6796 6805 10.1158/0008-5472.CAN-14-0079 25297631